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To rapidly detect early stage infections the innate immune system maintains an 
assortment of pathogen recognition mechanisms interspersed throughout both the 
extracellular and intracellular environments. These sensors recognize key components 
of viral, bacterial and fungal pathogens, and stimulate an inflammatory response which 
leads to the expression of an extensive network of host defense proteins. One such 
canonical network is regulated by type I interferon. This pathway responds to viral 
infections by upregulating hundreds of interferon stimulated genes (ISG) critical for host 
immunity.  
One of the more pivotal proteins for viral control is interferon-induced 
transmembrane protein 3 (IFITM3). IFITM3 is a host protein known to play a key role in 
inhibiting numerous virus infections, including influenza, Dengue, West Nile, HIV and 
Ebola. It is active in the early stages of infection and interferes with viral fusion and 
content delivery to the cell cytoplasm. Despite this broad antiviral activity, the exact 
mechanism of IFITM3 viral fusion interference, and whether it directly interacts with the 
fusion environment remains unknown.    
To better understand the physiological conditions of IFITM3 antiviral activity, we 
required an improved understanding of the endogenous levels of S-fatty acylation. 
While earlier work in our lab has shown this post-translational modification to be critical 
for IFITM3 activity, it was previously impossible to distinguish between different modified 
populations. I therefore developed the acyl PEG exchange (APE) assay. Utilizing 
cysteine selective mass tags, APE detects different levels of fatty acylated cysteines 
within a protein population, which allows us to probe the lipidated states of endogenous 
proteins for the first time. Using this assay, I have shown that the majority of 
endogenous human IFITM3 is dually S-fatty acylated.   
To investigate the mechanism of IFITM3 antiviral activity, I generated 
recombinant, native, synthetically lipidated protein for structural and fusion-based 
studies. We applied an in vitro viral fusion model that detects the lipid mixing of viral 
envelopes with liposomes. We demonstrate that viral fusion is mitigated with the 
inclusion of recombinant IFITM3 liposomes. Furthermore, when IFITM3 is modified with 
maleimide palmitate to mimic fatty-acylation at cysteine 105, lipid mixing is inhibited 
more than the unmodified IFITM3.   
Overall, our recombinant model of viral fusion provides an in vitro approach to 
investigate IFITM3 function. The assay provides the first evidence that IFITM3 directly 
alters the membrane fusion environment, and that cysteine palmitoylation enhances 
protein function as well. In the future, these studies will be complemented with more 




Like any modern achievement, this work has been made possible thanks to a village. I 
am indebted to several individuals and groups, who throughout the years have been 
pillars of support to either my spirit or my lab supplies. A heartfelt thank you to: 
My thesis advisor Dr. Howard Hang, for years of invaluable input and feedback, and 
always having an open door. 
My thesis committee members, Dr. Sanford Simon and Dr. Charles Rice, for providing 
an annual reality check and reassurance that I’m on the right track. 
The Hang lab for being there to help whenever needed. 
The Dean’s Office for their support, and handling my frequent and frantic questions. 




Chapter 1: Introduction to IFITM3 and S-fatty-acylation 1 
Chapter 2: Mass-tag labeling reveals site-specific and 
endogenous levels of protein S-fatty-acylation  
13 
Chapter 3: Characterization of endogenous IFITM3 S-fatty-
acylation.  
31 
Chapter 4: Generation of recombinant IFITM3 and lipidated 
isoforms.   
38 
Chapter 5: Production and anti-viral activity of IFITM3 
proteoliposomes.   
50 




LIST OF FIGURES 
Figure 1 Type I interferon activation pathway 2 
Figure 2 IFITM family evolution and IFITM1-3 sequence alignment 3 
Figure 3 Membrane Topology of IFITM3 4 
Figure 4 Possible mechanisms of IFITM3 inhibition. 7 
Figure 5 Proposed mechanism for IFITM3 disruption of cholesterol 
homeostasis. 
8 
Figure 6 Proposed mechanism for IFITM3 arrest of viral 
hemifusion. 
10 
Figure 7 Posttranslational modifications of IFITM3. 12 
Figure 8 Protein lipidation varies in chain length, saturation and 
site of attachment. 
14 
Figure 9 Schematic for S-fatty acylation detection and analysis 16 
Figure 10 APE enables the detection of S-fatty acylation levels. 18 
Figure 11 Optimization of APE. 20 
Figure 12 APE and metabolic labeling of HA-HRas. 21 
Figure 13 APE can be applied to proteins with varied topologies, 
molecular weights, and S-fatty acylation events. 
22 
Figure 14 mPEG-Mal concentration optimization of IFITM3. 32 
Figure 15 Murine IFITM3 APE PEGylation levels and antiviral 
activity. 
33 
Figure 16 APE of endogenous murine IFITM3. 34 
Figure 17 APE and antiviral activity of human IFITM3. 37 
Figure 18 Purification of recombinant IFITM3 39 




Figure 20 Mal-palm labeling of rIFITM3 S-fatty acylation isoforms. 42 
Figure 21 Mal-palm labeling optimization and mass-spec 
confirmation. 
44 
Figure 22 Rapid dilution of detergent solubilized lipid-protein leads 
to formation of unilamellar proteoliposomes. 
52 
Figure 23 Protein incorporation into the proteoliposome. 54 
Figure 24 Calculation of IFITM3 concentration per LUV and lipid 
bilayer leaflet. 
55 
Figure 25 VDID labeled IAV enables detection of envelope lipid 
mixing. 
56 
Figure 26 Fusion comparison of LUV lipid compositions. 58 
Figure 27 Temperature of IAV fusion affects rate, and signal 
saturation 
60 
Figure 28 Viral fusion with LUV is pH, HA dependent. 61 
Figure 29 Titration of VAMP2 and apoIFITM3 confirms dynamic 
range of proteoliposome fusion assay. 
63 
Figure 30 ApoIFITM3 inhibits viral lipid mixing to a greater degree 
than VAMP2. 
64 
Figure 31 All constructs of IFITM3 inhibit viral lipid mixing. 65 
Figure 32 Cys specific lipidation of IFITM3 salters inhibition of DiD 
dequenching. 
66 
Figure 33 Residual mal-palm, chymotrypsin treatment does not alter 
proteoliposome fusion properties. 
68 
Figure 34 Labeling of IAV with BCN-NHS-Ester enables fluorescent 
detection of IAV capsid proteins by SDS-PAGE 
77 
Figure 35 Lipid composition of late endosome, and proposed model 
composition. 
79 
Figure 36 Single particle measurements for improved 
characterization of viral fusion. 
81 




LIST OF TABLES 
Table 1 Antiviral activity of IFITM family 5 
Table 2 Sizes and formation techniques for unilamellar liposomes. 50
1 
Chapter 1: Introduction  
IFN-Induced Innate Immunity  
The interplay and kinetics of pathogenic infections necessitates persistent, basal level 
cell surveillance and rapid early response capabilities. The broadly conserved first line 
of defense, the innate immune system, is a non-adaptive response triggered by 
commonly conserved, pan-pathogen motifs (pathogen-associated molecular patterns, 
PAMP). These bind to pathogen recognition receptors (PRRs) to activate the secretion 
of inflammatory cytokines 1, which in turn upregulate a broad range of defense proteins 
in immune and non-immune cells alike that disrupt pathogenicity and infection. The 
innate inflammatory response is critical for orchestrating changes in gene expression2 
that provide a crucial line of defense for early stage infection, and facilitates the 
development of the adaptive immune response as well3. Despite adaptive immunity 
being critical for late stage infection and clearance intracellular defense mechanisms 
contain no adaptive capabilities, rendering the innate response the key means of 
disrupting intracellular pathogen infection. 
One of the canonical inflammatory pathways is that of the interferon (IFN) 
cytokines, which play a critical role in innate defense4. Mediated through the JAK/STAT 
pathway (Fig.1), activation results in the upregulation of hundreds of interferon-
stimulated genes (ISG) that alter the cellular and tissue environment as well as detect 
and combat viral replication, entry, and cell-to-cell dissemination5. IFNs are classified 
into three different types – type I IFN (IFNα and IFNβ)4 type II (IFNγ)6, and type III 
(IFNλ)7. While type I activation is considered the primary pathway for ISG activation, 
increasing evidence is emerging for type III activation in a tissue-specific manner7, 
2 
suggesting a more tightly regulated and temporally controlled expression of ISG antiviral 
activity. 
Figure 1. Type I interferon activation pathway. From Mcnab et al. Nat Rev Immunol. 
(2015)4. IFN expression is activated with the detection of PAMPs by a variety of PRRs 
located in the cytoplasm, at the plasma membrane, and the endosomal lumen. Binding 
of secreted IFN with receptors results in the upregulation of hundreds of different ISGs, 
priming nearby cells to express antiviral proteins. 
Interferon-Induced Transmembrane Protein 3:   
Within the broad group of interferon-stimulated genes (ISG), members of the interferon-
induced transmembrane protein (IFITM) family have emerged as potent restrictors of 
viral infection. Detected as an antiviral protein from a siRNA genomic screen searching 
for host factors critical for influenza A virus (IAV) infection8, IFITM3 is an essential host 
factor for viral innate defense, restricting a panoply of viruses9 entering through the 
endosomal pathway, in particular IAV10. As the IFITM family is the first ISG known to 
interfere with viral infection during fusion and content entry, considerable interest has 
emerged in understanding their characterization and mechanism. 
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IFITM orthologues are widely conserved among vertebrates11, with the human 
IFITM family having emerged during primate evolution12. Human IFITMs include IFITM 
1, 2, 3, 5, and 10, though only IFITM1, 2, and 3 exhibit antiviral activity. IFITM10 has a 
yet unknown function. IFITM3 predates the divergence of IFITM1, and IFITM2, which is 
only found in gorillas, chimpanzees, and humans. Sequencing alignment of IFITM1 ,2, 3 
shows similar size and domain conservation, except for IFITM1 which has lost its N-
terminal domain (Fig. 2). Both our lab and others13,14 have shown IFITM2 and 3 to 
contain an N-terminal YEML sorting motif that results in IFITM2 and 3 trafficking via the 
plasma membrane into the endosomal pathway. IFITM1, which has lost this motif in its 
N-terminus, is thought to localize to the plasma membrane. 
IFITM1      ---------------------MHKEEHEVAVLGPPPSTILPRSTVINIHSETSVPDHVVW  39 
IFITM2      MNHIVQ-TFSPVNSGQPPNYEMLKEEQEVAMLGVPHNPAPPMSTVIHIRSETSVPDHVVW  59 
IFITM3      MNHTVQTFFSPVNSGQPPNYEMLKEEHEVAVLGAPHNPAPPTSTVIHIRSETSVPDHVVW  60 
* ***:***:** * .   * ****:*:***********
IFITM1      SLFNTLFLNWCCLGFIAFAYSVKSRDRKMVGDVTGAQAYASTAKCLNIWALILGILMTIG  99 
IFITM2      SLFNTLFMNTCCLGFIAFAYSVKSRDRKMVGDVTGAQAYASTAKCLNIWALILGIFMTIL  119 
IFITM3      SLFNTLFMNPCCLGFIAFAYSVKSRDRKMVGDVTGAQAYASTAKCLNIWALILGILMTIL  120 
  *******:* *********************************************:*** 
IFITM1      FILLLVFGSVTVYHIMLQIIQEKRGY  125 
IFITM2      LIIIPVLVVQA-QR------------  132 
IFITM3      LIVIPVLIFQA-YG------------  133 
Figure 2. IFITM family evolution and IFITM1-3 sequence alignment. (A) Modified 
gain/loss phylogenetic tree from Compton et al. EMBO reports (2016)12. Asterisk marks 
evolutionary appearance of IFITM2. (B) Sequence alignment of human IFITM1, 2 and 3. 





IFITM3 membrane topology is a critical factor in exploring possible interactions 
and mechanisms of interference. Earlier work in our lab using cytoplasmic lipidation 
motif reporters15, and work by others showing the association of IFITM3 with μ2 AP-2 
proteins14 and flow cytometry-based surface labeling16 provide strong evidence that the 
N-terminal domain is cytoplasmic facing. In contrast, conflicting reports of the C-terminal 
topology leave it unclear whether it contains a transmembrane, or amphipathic domain 
13,16. Recent EPR and NMR data of recombinant protein indicates IFITM3 contains one 
transmembrane domain (therefore a type II membrane protein)17, though this data was 
obtained with DPC micelles (not a lipid bilayer), and with protein that was denatured 
during purification(Fig. 3). While promising, additional studies will be necessary to 
confirm the exact topology in the appropriate environment. 
Figure 3. Membrane topology of IFITM3. (A) NMR/EPR predicted topology and (B) 
respective model of IFITM3, proposed by Ling et al. Science Reports, 2016 17. 
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Since the first reports on IFITM3 antiviral activity against IAV and Dengue8, a 
considerable body of work has emerged elucidating the range of viruses susceptible to 
inhibition. This research has shown IFITM3 to be active against most clinically relevant 
viral pathogens (Table 1). It has also established the importance of IFITM3 in different 
tissues such as the lung18, liver19 and spleen20, and diverse cell types, including 
epithelial cells18, fibroblasts21, dendritic cells22, and CD8+  T cells23. 
Table 1.  Antiviral activity of IFITM family. Updated table from Smith et al. 9: ‘X’, viral 







Active IFITM Reference 
Orthomyxoviridae Influenza A virus < pH 6 ✔ 2,3 8, 28,61 
Influenza B virus <pH 6 ✔ 1-3 74 
Flaviviridae West Nile virus pH >6 ✔ 1-3 8, 21 
Zika Virus <pH 6 ✔ 3 24
Dengue virus <pH 6 ✔ 1-3 8 
Hepatitis C virus pH >6 ✔ 1-3 8, 19,25
Rhabdoviridae Vesicular stomatitis 
virus 
pH >6 ✔ 1–3 26,27
Rabies virus <pH 6 ✔ 2–3 24 
Lagos bat virus <pH 6 ✔ 2–3 24 
Filoviridae Marburg virus ɸ ✔ 1–3 28
Ebola virus ɸ ✔ 1–3 29 


























✔ 1 best 34 
Moloney leukemia 
virus 
X X No 8, 29 
Arenaviridae Lassa virus pH >6 X No 8 





X No 8 
Togaviridae Semliki forest virus pH >6 ✔ 1 and 3 34 
Chikungunya <pH 6 
✔ 
3 35 
Bunyaviridae La Crosse virus <pH 6 ✔ 1-3 36 
Hantaan virus <pH 6 ✔ 1-3 37 
Andes virus <pH 6 ✔ 1-3 37 








<pH 6 X No 37 
Reoviridae Reovirus   <pH 6  ✔ 3 37 
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Proposed mechanisms of IFITM3 anti-viral activity.  
IFITM3 restriction of viral infection occurs at the stage of viral fusion and content 
delivery38, focusing proposed models for IFITM3’s mechanism of antiviral activity on 
alternations to the environment in which viral fusion often occurs–the late endosome. An 
unbiased conjecture of possible mechanisms include (1) an indirect mechanism 
whereby IFITM3 recruits a yet unknown protein/cofactor responsible for the alternation 
of the fusion environment, either by changing membrane properties, or by altering the 
maturation pathway of the endosomal vesicle. (2) A direct mechanism, in which IFITM3 
alters the endosomal membrane’s biophysical properties such as membrane fluidity or 
curvature capacity, or (3) the maturation of the endosomal vesicle, directing the viral 
particle to an incompatible environment. (4) IFITM3 directly interacts with the viral 
particle, interfering with the completion of fusion (Fig. 4). 
Figure 4. Possible mechanisms of IFITM3 inhibition. IFITM3 inhibits viral fusion and 
content delivery via a yet unknown mechanism. This interaction either acts indirectly, 
recruiting an unknown protein/cofactor, or directly by disrupting the membrane fusion 
environment.  
8 
There are currently two models for IFITM3’s antiviral restriction, each suggesting 
distinctly different mechanisms: In 2013, Amini-Bavil-Olyaee et al. proposed that IFITM3 
interferes with viral entry by disrupting cholesterol export from the late endosome39. 
They showed that IFITM3 co-immunoprecipitates with vesicle associated membrane 
protein-A (VAP-A), that is part of the cholesterol export pathway mediated by NPC-2/1 
and ORP family proteins40. As the antiviral activity of IFITM3 is impaired with the 
overexpression of VAP-A, they posit that IFITM3 inhibits VAP-A, and that this interaction 
is overridden by sufficiently saturating the system with VAP-A protein. As they 
additionally show an increase in late endosome cholesterol in cells overexpressing 
IFITM3, they propose that the interaction between IFITM3 and VAP-A interferes with 
ORP-mediated cholesterol export, resulting in greater rigidity of the membrane, thus 
impeding fusion and retaining the viral particle until it is degraded in the lysosome (Fig. 
5).  
Figure 5. Proposed mechanism for IFITM3 disruption of cholesterol homeostasis. 
Fig. 7 from Amini-Bavil-Olyaee et al39. Left: under basal level conditions, cholesterol is 
trafficked out of the late endosome through NPC1/2 to ORPs and ER-bound VAP-A. 
Right: IFITM3 was proposed to interact with VAP-A, disrupting its interaction with ORP 
and increasing cholesterol levels and membrane rigidity within the late endosome.  
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In contrast, in 2014, Desai et al.27 proposed that as an alternative to cholesterol 
homeostasis, IFITM3 interferes with fusion pore formation, arresting late stage virus 
entry at the point of hemifusion (in which the outer membrane leaflet of the viral 
envelope mixes with the endosomal membrane, but the inner leaflet remains intact)(Fig. 
6). Using a panel of membrane-binding fluorophores, and fluorescent nucleocapsid 
proteins, they demonstrated that with the overexpression of IFITM3, similar or 
heightened levels of envelope-lipid mixing occurs, reflecting either hemifusion, or 
complete fusion. Combined with a significant IFITM3-driven decrease in viral content 
delivery, these two data sets indicate that the viral particles initiate membrane fusion, 
but are obstructed from completing the fusion process, retaining the hemi-fused virus 
within the endosome and targeting it for degradation. Critically, they additionally show 
that this mechanism is independent of cholesterol levels, and that induced accumulation 
of cholesterol does not alter fusion and binding properties in A549 lung epithelial cells. 
While this model presents an alternative IFITM3 function, they were unable to 
confirm a precise molecular mechanism. This renews the question of direct vs. indirect 
interactions, though additional publications have shown IFITM3 interfered with cell-cell 
fusion in two separate models26,34. Considering the extensive differences between the 
plasma and endosomal membrane both in lipid and protein composition, these 
experiments reinforce the hypothesis that the mechanism is through a direct interaction 
of IFITM3 with the membrane that alters the lipid properties in some manner so as to 
inhibit fusion. 
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Figure 6. Proposed mechanism for IFITM3 arrest of viral hemifusion. Figure 8 from 
Desai et al.27. Instead of altering cholesterol homeostasis, IFITM3 was proposed to 
arrest viral hemifusion. As the paper was unsuccessful in detecting colocalization 
between the viral particles and IFITM3, it is still unclear whether it is a direct interaction.  
Though IFITM3’s inhibition of viral fusion and entry has been a primary research 
focus, additional IFITM3 functionalities have been reported, suggesting a more complex 
role in host defense: Though a host protein, IFITM proteins can be incorporated into 
budding viral particles32,41, thus impairing their assembly and infectivity. IFITM3 also 
plays a role in supporting adaptive immunity and regulating inflammation–memory CD8+
T cells in the lung parenchyma express higher levels of IFITM3, increasing their 
resistance to secondary infections23. Respiratory DC cells from IFITM3 KO mice 
showed increased susceptibility to influenza infection, leading to impaired trafficking to 
lymph nodes, and CD8+ activation22. Additionally, IFITM3 was shown to be critical for 
regulating IL-6 expression and lymphocyte survival in CMV infection20, as well as down 
regulating IRF3-mediated IFN-β expression during viral infection42. 
11 
Posttranslational modifications regulate IFITM3 traffic and activity 
IFITM3 is regulated by several post-translational modifications (PTMs) that 
alternately affect its antiviral activity (Fig. 7). Using metabolic labeling with the 
biorthogonal chemcial reporter alkyne-palmitate (alk-16), our lab has shown that all 
three cysteines (Cys) in IFITM3 are S-fatty-acylated, and that mutagenesis of these 
residues to alanines (Ala) critically impairs its antiviral activity13. The trafficking of 
IFITM3 is also regulated by the phosphorylation of tyrosine 20, which leads to diffuse 
localization (in contrast to a punctuate morphology) and loss of antiviral activity43,44. 
IFITM3 is further modified by the ubiquitination of lysines 24, 83, 88 and 10413, and the 
methylation of lysine 8845, both of which have been shown to disrupt antiviral activity. 
The disruption of ubiquitination by mutation of the individual lysines reduced IFITM3 
protein turnover and increased its anti-viral activity. Since our laboratory discovered 
IFITM3 S-fatty-acylation15, we have been especially interested in understanding how 
this dynamic modification quantitatively controls IFITM3 antiviral activity. 
12 
Figure 7. Posttranslational modifications of IFITM3. Schematic of IFITM3 PTMs: 
while Tyr20 phosphorylation, methylation at Lys 88 and ubiquitination (Ub) at Lys 
24,83,88,104 interfere with IFITM3, Cys palmitoylation is essential for its antiviral 
activity.  
Our understanding of IFITM3 physiology and scope of antiviral activity has been 
increasing over the past years. Nevertheless, these efforts have yielded mixed results in 
elucidating the molecular mechanism of IFITM3 activity, prompting the exploration of 
alternative experimental models. The following chapters describe our efforts towards 
characterizing the endogenous state of S-fatty-acylated IFITM3, generating recombinant 
protein, and its application to reconstituted liposomes for in vitro virus fusion assays. 
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Chapter 2: Mass-tag labeling reveals site-specific and 
endogenous levels of protein S-fatty acylation  
S-fatty acylation: a dynamic post-translational modification. 
The covalent coupling of fatty acids and similar carbon chain homologues to 
proteins provides the cell with a spatiotemporal mechanism for controlling protein affinity 
for membranes. These modifications affect stability, function, trafficking, and membrane 
composition preferences46. In eukaryotic cells, long chain fatty acid modifications 
primarily occur with lipids 12-18 carbons long, varying in saturation and attachment 
loci47 (Fig 8A). 
S-fatty acylation, which couples fatty acids to cysteines through a thioester bond, 
is primarily in the form of a saturated 16-carbon chain48 and is the most common 
eukaryotic post lipid modification to be dynamically modified47. S-fatty acids are coupled 
to proteins through protein acyl transferases (PATs), containing a DHHC catalytic 
domain49. In humans, there are 23 different DHHC family proteins, though substrate 
redundancy has complicated our understanding of targets. The cleavage of S-fatty acids 
is mediated by acyl-protein thioesterase (APT)1/250, PPT151 and ABHD1752 (Fig. 8B), 
though considering the broad profile of S-acylated proteins, more are likely to be 
discovered. As the immune system must self-regulate inflammation to avoid an 
excessive response and immunopathology53,54, the dynamic nature of S-fatty acylation 
has prompted interest in understanding what role it potentially plays in innate and 
adaptive immunity. 
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Figure 8. Protein lipidation varies in chain length, saturation and site of 
attachment. (A) Comparison of lipidation modifications varying in structure and site of 
attachment. Table from Chamberlain et al.47, modified to include lysine deacylation by 
SIRT255. (B) S-palmitoylation is dynamically regulated, with the addition and cleavage of 
the fatty acid regulated by DHHC-PATs and thioesterases, respectively. 
Our expanding knowledge of the role of S-fatty acylation in influencing numerous 
cellular activities has driven the field’s continued investment in improved methods for S-
fatty acylation detection, and understanding of dynamics and regulation56. Proteome 




enrichment techniques that can target either endogenous proteins, or proteins labeled 
by exogenous tags incorporated through the cellular machinery (metabolic labeling)57. 
These tags – alkyne-modified fatty acid chemical reporters (Fig. 9A) – utilize 
bioorthogonal Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC)58 to label proteins for 
analysis by polyacrylamide gel electrophoresis (PAGE), or enrich for characterization by 
mass spectrometry. This approach has been developed57 and used by our lab15,59 to 
generate whole cell profiles that provide a first step towards discovering new 
modifications. 
As an alternative to metabolic labeling, thioester specific cleavage of 
hydroxylamine (NH2OH) has enabled the enrichment of endogenously labeled S-fatty 
acylated proteins by acyl-biotin exchange (ABE)60, and the acyl-resin capture (acly-
RAC)61. These methods overcome technical limitations inherent with metabolic labeling, 
and can detect S-fatty acylated proteins under physiological conditions, including ex-
vivo tissue samples inaccessible to chemical probes62. They have yielded invaluable 
profiles of endogenous lipo-proteomes, characterizing both cell types63-66 and tissues67-
69. Recent advances in experimental design have also enabled Cys specific detection of
site modification, streamlining initial detection and site validation into a single data set70. 
16 
Figure 9. Schematic for S-fatty acylation detection and analysis. (A) For metabolic 
labeling, cells are incubated with alkyne-labeled palmitate (alk-16) for several hours 
prior to harvesting. Proteins are lysed, reacted with azide-functionalized reagents by 
CuAAC, and analyzed by in-gel fluorescence, or processed for proteomics57. (B) With 
ABE or acyl-RAC, cell lysates are capped with NEM, and the thioesters cleaved with 
NH2OH. The newly generated cysteines are reacted with HPDP-Biotin71. Following 
streptavidin bead enrichment, captured proteins are eluted with reducing agents and 
then analyzed by Western blot or processed for proteomics59.  
Albeit these advances and methodological iterations, several limitations have 
persisted in quantitatively characterizing S-fatty acylation with these assays; S-acylation 
levels (the number of fatty acids on a single protein) cannot be differentiated, nor could 
the ratio between S-fatty acylated, and non S-fatty acylated protein (apo) be detected 




addition of exogenous source of chemical reporters, veering further away from 
physiological conditions. We therefore sought to develop a new method capable of 
detecting the different S-fatty acylation levels present in a protein population. This would 
advance the fields ability to understand how changes in S-fatty acylation levels alter 
downstream phenotypes such as localization and function. 
To resolve a protein’s levels of S-fatty acylation, we have developed acyl-PEG 
exchange (APE)71. This method utilizes the selective cleavage of thioesters by NH2OH 
to cleave S-fatty acids, exposing nucleophilic thiols which are then labeled with tags of 
defined molecular weight. These coupled ‘mass tags’ of maleimide-functionalized 
polyethylene glycol (mPEG-Mal) result in a mobility shift when analyzed by gel 
electrophoresis, corresponding to the original number of S-fatty acylated cysteines. APE 
enables facile detection of multiple S-fatty acylation populations of proteins, without the 
drawback of affinity enrichment, or the interference of exogenous chemical reporters 
(Fig. 10A). 
For APE, cell samples are lysed in denaturing buffer (4% SDS), and the free 
cysteines reduced with TCEP and capped with N-ethyl maleimide (NEM). After excess 
NEM is removed by protein precipitation, thioesters are cleaved by incubating the 
resuspended sample with NH2OH. Excess NH2OH is removed, and the exposed 
cysteines are labeled with mPEG-Mal, before analysis by SDS-PAGE and western blot. 
We first applied APE to the canonical S-palmitoylated protein HRas (Fig. 10B). A 
peripheral membrane GTPase involved in cell division, HRas contains two S-
palmitoylation sites (Cys 181, 184), as well as one thioether coupled (and therefore 
NH2OH insensitive) farnesyl group at Cys 18672. To compare our overexpressed HA-
18 
tagged HRas with endogenous level proteins, we also blotted against endogenous 
calnexin, an ER chaperon protein with two known S-palmitoylation sites73.  
Figure 10. APE enables the detection of S-fatty acylation levels.  (A) Schematic for 
APE protocol. Samples are lysed, reduced and capped with NEM. The thioesters are 
then cleaved with NH2OH, labeled mPEG-mal, and analyzed by SDS-PAGE and 
Western blot. (B) HA-HRas was analyzed by APE with different controls.  With the 
sequential addition of NEM, NH2OH, and mPEG-mal, mass shifts reflecting different 




The incubation of HEK293T cell lysates with mPEG-Mal alone (lane 2) results in 
several mass shifts, corresponding with the varying availability of non-modified 
cysteines. With the addition of NEM prior to mass-tag labeling (lane 3), all cysteines are 
fully capped, resulting in no mass-shift. The addition of the NH2OH (lane 4) exposes 
previously S-fatty acylated cysteines, which are successfully labeled with mPEG-mal. 
HRas displays two mass shifts, reflecting single (*) and doubly (**) labeled populations, 
corresponding with its dynamic spatial regulation through S-fatty acylation72. Additional 
shifts were not observed, suggesting successful NH2OH resistance of non-thioester 
based modifications. Calnexin (CANX) exhibits two mass shifts as well, in agreement 
with the literature on the known S-fatty acylation sites.  To show that our mass shifts are 
dependent on the size of our mass-tags, samples were additionally labeled 10 kDa 
mPEG-mal (lane 5). Indeed, the larger molecular weight mass tag exhibited a mass shift 
twice the size of the 5 kDa tag, confirming a tag-dependent shift. 
Having demonstrated a proof-of-concept - that APE can label S-fatty acylated 
proteins, the protocol was optimized to ensure complete capping, cleavage and 
labeling. A titration of the amount of NH2OH during a one hour incubation showed 
saturating levels were obtained at 0.75 M (Fig. 11A). Saturating levels for mPEG-mal 
varied depending on the molecular weight of the protein analyzed (Fig. 11B), though we 
discovered that some proteins, such as Rab7 present a mPEG-mal dependent mass 
shift even without NH2OH. The presence of 0.1 % Triton X-100 (copied from the ABE 
protocol) did not end up affecting our results with our specific proteins (Fig. 11C) though 
a critical experimental component was shown to be the inclusion of EDTA during the 
cleavage of NH2OH (Fig. 11D). 
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Figure 11. Optimization of APE. (A) APE does not require 0.2% Tx-100, though 
removal of EDTA impairs the completion of di-PEGylation for CANX and endogenous 
Ras. (B) The removal of EDTA from various stages of APE confirms it essential for 
NH2OH cleavage. Titration of NH2OH (C) and mPEG-mal (D) reveals that saturating 
conditions are protein specific. GFP-RAB7 exhibits an NH2OH independent mass shift, 
stressing the importance of proper optimization before further assays.  
To confirm the observed APE mass shifts are site specific, we compared HA-
HRas constructs containing single and double cysteine to alanine mutations (Fig. 12A). 




how the results compared between the two assays (Fig. 12B). HEK293T cells were 
transfected overnight with the HA-HRas constructs, and incubated with 50 μM alk-16 
probe two hours prior to lysis. By APE, the absence of either or both S-palmitoylated 
cysteines results in distinct mass shift patterns corresponding with the number of 
available sites; single (C181A, C184A) cysteine constructs exhibited only one shift, 
while double (C181,184A) cysteines did not shift at all. Alk-16 labeling exhibited similar 
trends in signal, reflecting total S-fatty acylation in the sample. 
Figure 12.  APE and metabolic labeling of HA-HRas.  293T cells transfected with HA-
HRas constructs were incubated with 50 μM alk-16 and split for analysis by APE (A) 
and metabolic labeling (B). APE displays mass shifts corresponding with the number of 
Cys present in the HRas construct. For metabolic labeling, samples were lysed, 
immunoprecipitated with anti-HA beads, and labeled with azido-rhodamine by CuAAC 
prior to SDS-PAGE.  
To further demonstrate the applicability of APE, we analyzed several additional 
proteins that differ in topology, size and number S-fatty acylation sites (Fig. 13): CD9, a 
tetraspanin with 6 reported S-fatty acylation sites74, showed 4 shifts. IFITM3, a single 
pass membrane protein with three known sites, showed three shifts, and IRGM1, a 
peripheral GTPase displayed a single shift. Additionally, pan-Ras antibodies were used 
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to observe endogenous Ras, which exhibited double and single mass shifts. The 
successful labeling of a variety of proteins provides strong evidence for the utility of 
APE. This assay equips us an accessible, novel analytical approach for S-fatty 




Figure 13. APE can be applied to proteins with varied topologies, molecular 
weights, and S-fatty acylation events. HEK293T cells were transfected with either 
WT or cysteine deficient (P∆) constructs of HRas (A), IFITM3 (B), CD9 (C), IRGM1 (D) 





Chapter 2 methods (Published in Percher et al. PNAS 2016) 
Acyl-PEG Exchange (APE)  
Cell samples were lysed with 4% sodium dodecyl sulfate (SDS, Fischer) in TEA 
buffer (pH 7.3, 50 mM triethanolamine (TEA), 150 mM NaCl) containing 1x protease 
inhibitor cocktail (Roche), 5 mM PMSF (Sigma), 5 mM EDTA (Fischer) and 1500 
units/mL benzonase (EMD). The protein concentration of the cell lysate was then 
measured using a BCA assay (Thermo), and adjusted to 2 mg/mL with lysis buffer. 
Typically, 200 µg of total protein in 92.5 µL of lysis buffer was treated with 5 µL of 200 
mM neutralized tris(2-carboxyethyl)phosphine (TCEP, Thermo) for final concentration of 
10 mM TCEP for 30 minutes with nutation. N-ethylmaleimide (NEM, Sigma), 2.5 µL from 
freshly made 1 M stock in ethanol, was added for a final concentration of 25 mM and 
incubated for 2 hours at room temperature. Reductive alkylation of the proteins was 
then terminated by methanol-chloroform-H2O precipitation (4:1.5:3) with sequential 
addition of methanol (400 µL), chloroform (150 µL) and distilled H2O (300 µL) (all pre-
chilled on ice). The reactions were then mixed by inversion and centrifuged (Centrifuge 
5417R, Eppendorf) at 20,000 g for 5 minutes at 4o C. To pellet the precipitated proteins, 
the aqueous layer was removed, 1 mL of pre-chilled MeOH was added, the eppendorf 
tube inverted several times and centrifuged at 20,000 g for 3 minutes at 4o C. The 
supernatant was then decanted, and the protein pellet washed once more with 800 µL 
of pre-chilled MeOH, centrifuged again and dried using a speed-vacuum (Centrivap 
Concentrator, Labconco) To ensure complete removal of NEM from the protein pellets, 
the samples were resuspended with 100 µL of TEA buffer containing 4% SDS, warmed 
to 37o C for 10 minutes, briefly (~5 seconds) sonicated (Ultrasonic Cleaner, VWR) and 
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subjected to two additional rounds of methanol-chloroform-H2O precipitations as 
described above. 
For hydroxylamine (NH2OH) cleavage and mPEG-maleimide alkylation, the 
protein pellet was resuspended in 30 µL TEA buffer containing 4% SDS, 4 mM EDTA 
and treated with 90 µL of 1 M neutralized NH2OH (J.T. Baker) dissolved in TEA buffer 
pH 7.3, containing 0.2% Triton X-100 (Fisher) to obtain a final concentration of 0.75 M 
NH2OH. Protease inhibitor cocktail or PMSF should be omitted, as these reagents can 
interfere with the NH2OH reactivity. Control samples not treated with NH2OH were 
diluted in 90 µL TEA buffer with 0.2% Triton X-100. Samples were incubated at room 
temperature for 1 hour with nutation. The samples were then subjected to methanol-
chloroform-H2O precipitation as described above and resuspended in 30 µL TEA buffer 
containing 4% SDS, 4 mM EDTA, warmed to 37o C for 10 minutes and briefly (~5 
seconds) sonicated and treated with 90 µL TEA buffer with 0.2% Triton X-100 and 1.33 
mM methoxypolyethylene glycol-maleimide (mPEG-Mal, 5 or 10 kDa, Sigma) for a final 
concentration of 1 mM mPEG-Mal. Samples were incubated for 2 hours at room 
temperature with nutation before a final methanol-chloroform-H2O precipitation. Dried 
protein pellets were resuspended in 50 µL 1 X Laemmli buffer (BioRad) and then heated 
for 5 minutes at 95o C. Typically, 15 µL of the sample was loaded in 4-20% Criterion-
TGX Stain Free polyacrylamide gels (Bio-Rad), separated by SDS-PAGE and analyzed 
by western blot. For western blots, primary antibodies used were anti-calnexin (1:2000 
ab22595, Abcam), anti-Pan Ras (1:500, Ras10, Millipore), anti-mouse IFITM3 (1:1000, 
ab15592, Abcam) anti-FLAG (1:1000, F1804, Sigma) anti-HA (1:1000, ab9134, Abcam), 
and HRP-conjugated anti-HA (3F10, Roche). Secondary antibodies used were HRP-
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conjugated goat anti-rabbit (DC03L, Calbiochem), and goat-anti-mouse (ab97023, 
Abcam). Protein detection was performed with ECL detection reagent (GE healthcare) 
on a BioRad ChemiDoc MP Imaging System 
Cell Culture and Transfections 
HEK293T, HeLa and RAW264.7 cells were obtained from ATCC. For transfection 
of HEK293T or HeLa cells, near confluent 6-well plates were transfected with 1 µg of 
plasmid DNA using 3 µL of Lipofectamine 2000 reagent (Life Technologies). After 24 
hours, cells were collected by scraping, centrifuged at 500 g for 2 minutes, washed with 
1X PBS, snap-frozen in dry ice/ethanol bath and stored at -80o C for future use. For 
NIH3T3 cells, near confluent 6-wells plates were transfected with 1 µg of plasmid DNA 
with 3 µL of Lipofectamine 3000 reagent (Life Technologies). After 6 hours, the media 
was replaced with fresh media to reduce toxicity of the Lipofectamine reagent. After 24 
hours the cells were collected and stored for future use at -80o C. LPS (500 ng/mL, 
Enzo Life Sciences) and IFN-γ (100 U/mL IFN-y, Thermo) activation of cells were 
performed as previously described13. 
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Acyl-Biotin Exchange (ABE) 
The ABE protocol was performed as described60. Following cell lysis, 400 µg of 
total cell lysate resubjected to reductive alkylation with TCEP and NEM as described 
above for the APE protocol. After the final methanol-chloroform-H2O precipitation, the 
protein pellet was resuspended in 100 µL 4% SDS in 50 mM TEA, 150 mM NaCl pH 
7.3, and 1 mM EDTA. The samples were split into two 50 µL aliquots and treated with 
1M NH2OH or control buffer (200 µg/condition). For the NH2OH-treated sample, 150 µL 
NH2OH-HPDP-biotin buffer (for 160 µL of buffer: 3.2 µL of HPDP-Biotin (50 mM stock in 
DMSO, Sigma), 36.8 µL of dimethylformamide (DMF, Fisher Scientific), 3.2 µL of 10% 
Triton X-100 in H2O, 112 µL of 1 M NH2OH in H2O pH 7.3, 4.8 µL H2O) was added to 
the sample for a final concentration of 0.75 M NH2OH, 1% SDS (lysate:NH2OH-HPDP-
biotin buffer 1:3). For the NH2OH-negative control, the samples were treated with 150 
µL of HPDP-biotin buffer (for 160 µL of buffer: 3.2 µL of HPDP-Biotin (50 mM stock in 
DMSO), 36.8 µL of DMF, 3.2 µL of 10% Triton x-100 in H2O, 16 µL of 500 mM TEA 1.5 
M NaCl pH 7.3, 101.8 µL H2O) was added to the negative control sample for a final 
concentration of 1% SDS (Lysate: Buffer 1:3). The mixture was incubated at room 
temperature with end-over-end rotation for 1 hour. Proteins were precipitated 
(methanol-chloroform-H2O precipitation) and resuspended in 50 µL 4% SDS 50 mM 
TEA pH 7.3, 150 mM NaCl, 1mM EDTA (final concentration 4 mg/mL). 150 µL HPDP-
biotin low concentration buffer (for 300 µL of buffer: 1.2 µL of HPDP-Biotin (50 mM), 
13.8 µL of DMF, 6 µL of 10% Triton X-100 in H2O, 30 µL of 500 mM TEA 1.5 M NaCl pH 
7.3, 249 µL H2O) was added to both samples (HPDP-biotin: lysate 3:1). The samples 
were incubated at room temperature with end-over-end rotation for 1 hour, subjected to 
27 
methanol-chloroform-H2O precipitation as described above and resuspended in 100 µL 
0.2% SDS 0.2% Triton X-100 50 mM TEA, 150 mM NaCl, pH 7.3. High-affinity 
streptavidin-agarose beads (Thermo, 20 µL of bead slurry/200 µg of protein) were 
washed with 50 mM TEA, 150 mM NaCl, 0.2% Triton X-100, pH 7.3 (3x). The 
resuspended samples were then added to the beads and incubated at room 
temperature with end-over-end rotation for 90 minutes. The supernatant from the beads 
was decanted and boiled with 4x Laemmli sample buffer (LSB) (supernatant:LSB:BME 
3:1:0.1) at 95° C for 5 min. The beads were washed with 1% SDS in PBS for 2 minutes, 
and centrifuged at 1700 g for 1 minute (2x). The beads were then washed in 4 M Urea 
(Sigma) in PBS (3x), PBS (3x). The beads were boiled at 95° C for 10 minutes with 1x 
Laemmli sample buffer (LSB:BME:4% SDS 50 mM TEA, 150 mM NaCl pH 7.3, 
0.9:0.1:3), separated by SDS-PAGE and analyzed by western blot. Typically, 40 µg of 
protein were loaded on the gel. 
Acyl-Resin Assisted Capture (acyl-RAC). 
Following reductive alkylation of total lysate (400 µg) with TCEP and NEM as 
described above for the APE and ABE, the samples were resuspended in 50 µL 4% 
SDS, 50 mM TEA, 150 mM, 150 mM NaCl, 1 mM EDTA, pH 7.3. The samples were 
split into two 25 µL aliquots - or + NH2OH (200 µg/condition). For the NH2OH-treated 
sample, 75 µL NH2OH 1 M, 0.2% Triton X-100, pH 7.3 in H2O was added to the 
“+NH2OH” sample for a final concentration of 0.75 M NH2OH, 1% SDS (Lysate: NH2OH 
solution 1:3). For the negative control not treated with NH2OH, 75 µL 50 mM TEA, 0.2% 
Triton X-100, 150 mM NaCl pH 7.3 was added to the samples (“-NH2OH”) for a final 
concentration of 1% SDS (Lysate:Buffer 1:3). To capture proteins with free thiols, thiol-
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sepharose beads 6B (T8387,Sigma) were soaked in 1 mL H2O for 30 minutes. Beads 
were washed three times with 0.5 mL of 50 mM TEA 150 mM NaCl, 0.2% Triton X-100, 
pH 7.3. Each sample (100 µL of -/+ NH2OH) was added to the thiol-sepharose beads 
(200 µg of proteins/6.25 mg thiol-sepharose beads) and incubated at room temperature 
for 3 hours with end-over-end rotation. The supernatants from the beads were decanted 
and boiled with 4x Laemmli sample buffer (LSB:BME:supernatant 0.9:0.1:3) for 5 min. 
The beads were washed with 1% SDS in PBS (3 x 2 min), 4 M Urea in PBS (3x), PBS 
(3x). Beads were boiled at 95o C for 10 minutes with 1x Laemmli sample buffer 
(LSB:BME:4% SDS 50 mM TEA, 150 mM NaCl pH 7.3, 0.9:0.1:3), separated by SDS-
PAGE and analyzed by western blot. Typically, 40 µg of protein were loaded on the gel. 
Metabolic labeling and in-gel fluorescence profiling 
For metabolic labeling of cells with alkyne-palmitic acid reporter (t), HEK293T 
cells transfected with HA-HRas constructs or NIH3T3 cells transfected with HA-
mIFITM3 constructs were incubated for two hours with 50 µM alk-16 (synthesized as 
previously reported ) in DMEM containing 2% (v/v) charcoal-dextran stripped FBS (Lot: 
AZA180873, HyClone). Cells were harvested by trypsinization, washed once in PBS, 
pelleted and lysed in 1% (w/v) Brij 97 (Sigma) in 50 mM TEA 150 mM NaCl pH 7.3 with 
5X concentration of EDTA-free protease inhibitor cocktail (Roche). Total protein 
concentration was measured by BCA assay (Life Tech). For immunoprecipitation, 200 
μg of total protein was added to 20 μL of anti-HA antibody–conjugated agarose (Sigma) 
in a total volume of 250 μL and rocked at 4° C for 16 hours. Agarose beads were 
washed twice by resuspension in 1 mL of wash buffer (1% Triton X-100, 1% sodium 
deoxycholate (Sigma), 0.1% SDS in 50 mM TEA, 150 mM NaCl pH 7.3) and centrifuged 
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at 3500 g for 30 seconds. The beads were then resuspended in 20 μL of 1% (w/v) Brij in 
in 50 mM TEA 150 mM NaCl pH 7.3 and 5 μL of CuAAC reactant solution (0.5 μL of 5 
mM azido-rhodamine (final concentration 200 μM), 1 μL of 50 mM freshly 
prepared CuSO4·5H2O in H2O (final concentration 2 mM, Sigma), 1 μL of 50 mM freshly 
prepared  TCEP (final concentration  2 mM) and 2.5 μL of 2 mM tris[(1-benzyl-1H-1,2,3-
triazol-4-yl)methyl]amine (TBTA) (final concentration 200 μM, synthesized as previously 
reported). Beads were rocked with the CuAAC reactant solution at room temperature for 
1 hour and washed twice with wash buffer as described above. The proteins were 
eluted addition of 30 μL 1X Laemmli sample buffer (LSB:BME: 4% SDS 50 mM TEA, 
150 mM NaCl pH 7.3, 1:0.1:3), heated for 5 minutes at 95° C and separated by SDS-
PAGE. In-gel fluorescence scanning was performed using a Typhoon 9400 imager 
(Amersham Biosciences). Western blots for HA-tagged proteins were performed using 
an anti–HA tag-HRP conjugated antibody (1/1,000 Roche). 
Influenza virus infection 
NIH3T3 cells were transfected with Lipofectamine 2000 (Thermo) overnight in 
12-well plates using 1 μg of plasmid per well.  Media was removed and replaced with 
400 μL of media +/- influenza virus strain A/Puerto Rico/8/34 (H1N1, commonly referred 
to as PR8) at an multiplicity of infection (MOI) of 5 for each well.  Infection was allowed 
to proceed for 18 hours. Cells were collected and fixed for 10 minutes with 4% 
paraformaldehyde.  Fixed cells were then permeabilized with 0.1% Triton X-100 in PBS 
for 10 minutes and blocked with 2% FBS in PBS for 20 minutes.  All antibody staining 
and washing was performed using the 0.1% Triton X-100 solution.  Staining with anti-
HA antibody (HA.11, Covance, 1:1000) was performed for 20 min at room temperature 
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followed by three washes and staining with anti-mouse secondary antibody conjugated 
to Alexafluor-488 (Life Technologies, 1:1000). After an additional three washes, cells 
were stained with anti-influenza NP antibody (ab20343, Abcam, 1:300) that was directly 
conjugated in-house to Alexafluor-647 using the 100 ug antibody labeling kit from Life 
Technologies.  Samples were analyzed using a Becton Dickinson FACSCanto II flow 
cytometer and HA-positive cells were analyzed for the percentage of cells staining 
positive for influenza NP indicating cellular infection using Flowjo software as previously 
described. 
Immunofluorescence analysis 
For the analysis of mIFITM3 colocalization with endosomal/ lysosomal markers, 50,000 
NIH3T3 cells/well were plated in a 24 well plate, and co-transfected the next day with 
0.25 μg HA-IFITM3 and 0.25 μg of either GFP-Rab5, GFP-Rab7 (54244, addgene), or 
LAMP1-GFP (34831, addgene) with 1.5 μL Lipofectamine 3000 (Thermo) for four hours, 
then incubated with fresh media for an additional 12 hours. Cells were fixed for 15 min 
with 3.7% paraformaldehyde, washed 3x with PBS, permeabilized with 0.1% saponin in 
PBS for 10 minutes, and blocked for 60 minutes with 1% BSA in PBS. All antibody 
staining and washing was performed with 0.1% saponin in PBS. Cells were incubated 
with goat anti-HA antibody (1/1000, ab9134, Abcam) in 1% BSA for one hour at room 
temperature. After three, 5 minute washes, samples were incubated with donkey anti-
goat antibody conjugated to Alexafluor-647 (1/1000, A-21447, Invitrogen) in 1% BSA. 
Cells were washed, and mounted using ProLong Gold antifade reagent (Invitrogen). 
Images were obtained from an Inverted Zeiss Axio Observer Z1 microscope, and 
processed with ImageJ. Pearson coefficient was calculated using Imaris 8 software. 
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Chapter 3: Characterization of endogenous IFITM3 S-fatty 
acylation.  
Having confirmed with model proteins that APE can observe different levels of S-
fatty-acylation by western blot, we further explored the S-fatty acylation of IFITM3. 
Previous work in our lab has shown by alk-16 metabolic labeling that IFITM3’s three 
cysteines are S-fatty acylated, and that the mutation of all three to Ala disrupt anti-viral 
activity15. Additionally, the mutation of C72 alone was sufficient to disrupt anti-viral 
activity against IAV and Dengue virus10. While this suggests S-fatty acylation plays a 
role in IFITM3’s function, it was still unclear how many sites were modified 
simultaneously. Understanding S-palmitoylation levels would further our understanding 
of the physiological state of IFITM3, and how it relates to its anti-viral activity. 
S-fatty acylation levels of murine IFITM3 
We first analyzed murine IFITM3 (mIFITM3), as doing so furthers our 
understanding of S-fatty acylation levels in a commonly used model for in vitro13 and in 
vivo21,75 experimental assays. Incubation times for mPEG-mal and NH2OH were 
compared for background mass shifts and completion of cleavage respectively (Fig. 14). 
Both conditions showed complete labeling and cleavage under standard conditions 
used for other samples. To determine how specific Cys sites contribute to mIFITM3 S-
fatty acylation levels, overexpressed HA-tagged constructs were analyzed by APE and 
alk-16 metabolic labeling. Similar to earlier reports in DC2.4 dendritic cells13,  alk-16 
incorporation onto mIFITM3 decreased in a cysteine dependent manner(Fig. 15A); 
C71A and C105A showed a similar loss of labeling, while C72A showed the greatest 
decrease. 
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Figure 14. mPEG-Mal concentration optimization of IFITM3. NIH3T3 lysate was 
analyzed by APE with varying concentrations of mPEG-Mal. No change in ratios was 
observed at concentrations higher than 1 mM. The number of PEGylation events are 
indicated by asterisks (*).  
With APE, overexpressed WT IFITM3 displayed four distinct bands, reflecting the 
presence of non-modified (apo), mono, di, and tri-PEGylated populations (Fig. 15B, 2nd 
lane). In comparison, the individual and dually-mutated cysteines show distinct 
PEGylation patterns: the mutation of either Cys 71 or Cys 105 to alanine, shows two 
mass shifts (mono, and di-PEGylated) while the mutation of C72A shows only one (4th 
lane). To elucidate how Cys specific S-fatty acylation correlates with anti-viral activity, 
we next compared the differences in viral infectivity in cells transiently overexpressing 
the IFITM3 constructs (Fig 15C). C71A displayed similar infection levels to that of the 
WT, while the mutation of C72 or C105 interfered with viral inhibition. This data, 
combined with the metabolic labeling, indicate that S-fatty acylation levels of mIFITM3 
alter the anti viral activity. While it is impossible to discern whether a specific S-acylated 
population is more active, the dually mutated constructs show that the presence of a 
single S-fatty acylation site at Cys 72 (C71,105A) is sufficient to restore a significant 
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portion of the anti-viral activity. Cys 72’s contribution to protein function, together with 
the disruption of dual, and tri-PEGylated levels by APE suggests that its S-fatty 
acylation may play a key role in the anti-viral activity of the protein.  
Figure 15. Murine IFITM3 APE PEGylation levels and antiviral activity. (A) NIH3T3 
cells transfected with HA-mIFITM3 constructs were labeled for 2 hours with 50 μM alk-
16. Cell lysates were prepared with Brij-97, the HA constructs immunoprecipitated with
anti-HA agarose-beads, reacted with azide-rhodamine by CuAAC, separated by 
SDS/PAGE, and visualized by fluorescence gel scanning. (B) NIH3T3 cells were 
transfected with similar HA-mIFITM3 constructs and analyzed by APE. The number of 
PEGylation events are demarcated by asterisks (*). (C) NIH3T3 cells were transfected 
with HA-mIFITM3 constructs, followed by infection with PR8 influenza virus at a 
multiplicity of infection of 5, for 18 hours. Cells were fixed, permeabilized, stained with 
anti-influenza NP antibody and analyzed by flow cytometry. Graph shows anti-influenza 




Though the overexpressed constructs of IFITM3 are critical for understanding the 
role of Cys specific S-fatty acylation, our method of transient transfection results in non-
homogenous transfection, at higher expression levels than endogenous IFITM3 (data 
not shown). Both can potentially distort the levels of S-fatty acylation. We therefore 
determined the endogenous levels of S-fatty acylation levels of mIFITM3 in mouse RAW 
264.7 Macrophage, and NIH-3T3 fibroblast cell lines (Fig. 16).  Both cell types exhibited 
three mass shifts, with minimal apo-protein, indicating that the majority of endogenous 
IFITM3 is S-fatty acylated at least once. This data indicates 7 possible combinations of 
S-fatty acylation are physiologically present in cells. 
Figure 16. APE of endogenous murine IFITM3. Left: Possible S-fatty acylation 
isoforms observed by APE.  Mouse macrophage (Raw 264.7) and fibroblast (NIH3T3) 
cell lines were incubated overnight with IFN-γ and LPS, and analyzed by APE. The 
number of PEGylation events is indicated by asterisks (*). Right: APE mass shifts 
cannot discern between different combinations of S- acylation. Possible S-fatty acylation 
isoforms are described that would reflect a corresponding mass shift.   
C71A: Complete 
antiviral activity.  





APE analysis of S-fatty acylation levels of human IFITM3. 
Similar to mIFITM3, overexpressed human IFTIM3 (hIFITM3) in HEK293T cells 
show by APE three PEGylation levels for WT hIFITM3 (Fig. 17A). Both C71A, and C72A 
show primarily one PEGylation shift, of similar signal intensity, different slightly from the 
mIFITM3 constructs, where C71A contains two shifts. C105A shows two shifts, as 
observed in mIFITM3. For the double Cys mutants, the presence of Cys72 was 
sufficient to retain similar mono-PEGylated levels to the single Cys mutants. 
Interestingly, when containing only Cys 71, or Cys105 (C72,105A, C71,72A, 
respectively), a large decrease in signal was observed, suggesting an overall loss of S-
fatty acylation. 
We next compared the antiviral activity of the hIFITM3 Cys constructs (Fig. 17B). 
As with mIFITM3, C71A did not alter its activity, with similar levels of infected cells to 
that of WT. C72Ala had higher levels of infection, though less than the vector or triple 
mutant construct (C71,72,105A). With the double mutants, Cys71 alone (C72, 105A) 
resulted in a complete loss of function, while Cys72 alone (C71, 105A) retained partial 
levels of activity. Notably, distinct from mIFITM3, Cys105 alone (C71,72A) showed 
similar levels of antiviral activity to C71,105A.  This indicates that a minimal S-acylation 
construct of Cys105 is sufficient to retain a similar level of anti-viral activity to that of 
Cys72. For endogenous hIFITM3 S-acylation, A549 cells were analyzed by APE after 
overnight activation with IFN-у (Fig. 17C). A549, a human lung type II alveolar epithelial 
cell line 76, is a clinically relevant tissue type for investigating IFITM3 expression. 
Interestingly, a notable difference in APE PEGylation levels are observed in comparison 
to endogenous mIFITM3; the majority of the protein is dually-PEGylated, and no tri-
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PEGylated level is observed. This indicates that most of the protein is dually S-fatty 
acylated, and that six possible combinations are potentially present (Fig. 17D). As the 
disruption of Cys71 does not alter anti-viral activity, the likely S-acylated state of IFITM3 
in A549 is the dually-S-acylated C72,105. 
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Figure 17. APE and antiviral activity of human IFITM3. (A) HA-hIFITM3 constructs 
were expressed in HEK293T cells and analyzed by APE. PEGylation events are 
indicated by asterisks (*). (B) HEK293T cells transfected with wild-type, and cysteine 
mutant constructs of HA-hIFITM3, were infected with PR8 influenza virus at an MOI of 5 
for 18 h. Cells were fixed, permeabilized with 0.1% Triton X-100, and stained with anti-
influenza NP antibodies. Graph of influenza-NP+ cells for each condition. Error bars 
represent SEM, N = 3. (C) IFN stimulated A549 cells were analyzed by APE. 
PEGylation events are indicated by asterisks (*). (D) Depiction of possible S-fatty 










Chapter 4: Generation of recombinant IFITM3 and lipidated isoforms. 
Since the discovery of IFITM3 anti-viral activity38, a considerable body of work 
has been published on its localization, post-translational modifications13 and range of 
antiviral activity (table 1). While it has previously been shown that the point of 
interference is viral content delivery27,38, the mechanism of IFITM3 activity remains 
controversial. Conflicting reports make it unclear whether IFITM3 directly interacts with 
the virus, alters the late endosome membrane environment, or indirectly interacts with 
an unknown cofactor (Fig. 4). To eliminate the complexity of the cellular environment 
and selectively control potential key parameters of IFITM3’s mechanism (membrane 
lipid composition, protein concentration etc.) we directed our efforts towards the 
generation of recombinant human IFITM3 (rIFITM3). This enables a minimalist model of 
reconstituted protein in liposomes (proteoliposomes) and supported bilayers for viral 
fusion assays, allowing us to address whether IFITM3 alone is capable of inhibiting viral 
fusion. 
Generation of recombinant IFITM3. 
To minimize interfering factors, we designed the purification of rIFITM3 in a 
manner that limited denaturation of the protein, or retained any tags used for enrichment 
and purification17. We therefore utilized the His-SUMO tag that both increases the 
solubility of membrane proteins, and is cleaved C-terminal to the SUMO dual-glycine 
motif, generating native IFITM377 (Fig. 18B). Building off the purification conditions for 
the similarly sized SNARE membrane proteins78, we were able to enrich rIFITM3 at 
concentrations as high as 1 mg / mL, and isolate purified rIFITM3 through the use of 
size exclusion chromatography (SEC, Fig. 18C). 
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15 kDa 
WCL FT  W1  W2  W3  W4  1    2     3  4    5     6  7     8    9  10   11  
 10  11  12  13  14   15  16  17  18   19 Loading
Human IFITM3 6X HIS SUMO PET-28 28.3 kDa 
Sumo
IFITM3
Figure 18. Purification of recombinant IFITM3. (A) Schematic of rIFITM3 construct 
containing HIS tag, cleavable SUMO domain, and codon-optimized hIFITM3. (B) 
Immobilized metal affinity chromatography (IMAC) is used to enrich and purify rIFITM3. 
WCL: Whole cell lysate. FT: Flow through. W: Wash. (C) SEC improves purity of 









Lipidation of recombinant IFITM3. 
A critical aspect of generating rIFITM3 is replicating the correct post-translational 
modifications. To emulate S-fatty acylation, rIFITM3 constructs containing one or two 
Cys were modified with a maleimide-palmitate (mal-palm) to introduce a covalent 
saturated 16 carbon chain analog (Fig. 19). We have previously used maleimide 
(chapter 2) to specifically modify cysteines under similar conditions. 
To confirm that we can successfully label rIFITM3 with our mal-palm analog, we 
first tested and optimized the labeling of Cys72 on rIFITM3. Labeling with mal-palm 
resulted in a slower migration during analysis by SDS-PAGE. While the protein did not 
undergo complete labeling at 4 °C (Fig. 19B) , and precipitated at RT, we observed near 
complete labeling at 15 °C , in a Cys-specific manner, indicating the gel-shift was not 
due to background labeling. Labeling was further confirmed by MALDI-TOF mass 
spectrometry (Fig. 19C). 
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Figure 19. Mimicking S-fatty acylation of rIFITM3 with maleimide-palmitate. (A) 
Schematic of rIFITM3 labeling. Thiol-specific maleimide covalently labels rIFITM3, 
introducing a saturated 16 carbon chain. (B) Labeling optimization of Cys 72 rIFITM3. 
(C) Cysteine specificity of mal-palm. Cys 72 rIFITM3 (C71,105A) shows a Cys 
dependent mass shift when analyzed by SDS-PAGE. apoIFITM3 (containing no 
cysteines) under similar conditions does not shift. (D) MALDI-TOF confirmation of mal-
palm labeling.  
IFITM3 C71,72,105A 
14535.92 Dalton 
IFITM3 C71,105A + Mal-Palm  
14887.97 + 321.5  Dalton 
M/Z +1H +2H +3H M/Z +1H +2H +3H 
Expected 14536.93 7268.97 4846.3 Expected 14888.9 7444.9 4963.7 








Having confirmed that we can specifically label rIFITM3 Cys72, we generated a 
panel of mal-palm labeled rIFITM3 isoforms to determine whether site-specific lipidation 
alters the efficiency of anti-viral activity. Analysis of A549 cells by APE showed the 
majority of endogenous IFITM3 displayed two mass-shifts, indicating that most of 
IFITM3 is likely dually S-fatty acylated (Fig. 20). This reduced the complexity of our 
panel of rIFITM3 isoforms, as it implies that the triple-S-fatty acylated state does not 
occur in our tested human cell lines. As C71A does not compromise the anti-viral 
activity of hIFITM3 and a significant portion of activity was restored in the presence of a 
mono-lipidated Cys72, or Cys105 (Fig. 17B), we first generated three different mal-palm 
constructs: mono-lipidated C72 (ML-C72), mono-lipidated C105 (ML-C105), and dually-
lipidated C72,105 (DL-C72,105) (Fig 20). 
Figure 20. Mal-palm labeling of rIFITM3 S-fatty acylation isoforms. APE of A549 
cells reveal that the majority of endogenous IFITM3 is dually lipidated (**). To generate 
the relevant isoforms, mono-lipidated Cys 72, and 105 (*), and dual lipidated Cys 
72,105 were reacted with mal-palm.   
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To optimize labeling of rIFITM3 with mal-palm for the additional rIFITM3 
constructs, incubation times and concentrations were varied, and compared by SDS-
PAGE (Fig. 21A,B). The constructs were then labeled and purified under optimal 
labeling conditions and confirmed by MALDI-TOF mass spectrometry (Fig. 21C,D). 
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Figure 21. Mal-palm labeling optimization and mass-spec confirmation. (A) 
rIFITM3-Cys 105 was incubated with 1.0 mM TCEP and up to 2.5 mM Mal-Palm 
(controls were incubated with 5% DMSO). A single mass shift (*) was observed. Chosen 
conditions for future purifications are highlighted in red. (B) rIFITM3-Cys 72,105 was 
incubated with 1.0 mM TCEP and up to 1.0 mM mal-palm. Two discernible mass shifts 
were observed (*, **), though the majority of the protein signal was observed with the 
double shift. Chosen conditions for future purification are labeled in red. MALDI-TOF 
mass spectrometry confirmed single labeling of IFITM3 C71,105A (C), and double 
labeling of IFITIM3 C71A (D).  
IFITM3 C71,72A + Mal-Palm  
14567.98 + 321.5 Dalton 
M/Z +1H +2H +3H 
Expected 14889.99 7445.498 4964.003 
Observed 14893 7447.5 4962.8 
IFITM3 C71A + 2x Mal-Palm  
14600.04 + 2x 321.5 Dalton 
M/Z +1H +2H +3H 
Expected 15244.047 7622.527 5082.02 






Chapter 4 Methods: 
Generation of Recombinant IFITM3: 









Plasmid Construct Design: 
Sequence optimized IFITM3 was cloned by Gibson assembly into a PET 28c plasmid 
immediately 3’ to a HIS-Sumo sequence, designed by Christopher D. Lima79. For Cys 
mutant constructs, QuikChange Lightning, and QuikChange Multi Site-Directed 
Mutagenesis kits (Agilent) were used to mutate the needed number of cysteines to 
alanines. 
Induction and Enrichment of IFITM3 
The Sumo-IFITM3 construct was transformed into the BL-21 LOBSTR cell line80 
containing the RIL plasmid (BL21-CodonPlus-RIL strain, Agilent) for increased copies of 
tRNA argU (AGA, AGG), ileY (AUA), leuW (CUA). Single colonies were grown overnight 
in LB media containing kanomycin (50 μg / mL) and chloramphenicol (25 μg / mL). The 
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following day, overnight cultures were diluted 1:30 in 1 L LB with kanomycin, and 
incubated at 37 °C to an O.D. of 0.6 the culture was then transferred to 18 °C, induced 
with 0.5 μM IPTG, and incubated overnight for 16 – 20 h. The following day, aliquots of 
500 mL of cultures were spun down at 4,000 g for 15 min, and the bacterial pellet snap 
frozen in liquid nitrogen for future use. On the day of purification, a 500 mL bacterial 
pellet was thawed on ice, and resuspended in 40 mL Buffer A (25 mM HEPES, 100 
mM KCl, pH 7) with 2% w/v Triton-X 100, and 1x protease inhibitor mixture (Roche). If 
the purified protein contained any cysteines, 1 mM β-mercaptoethanol (Sigma) was 
added. The resuspended pellet was incubated at room temperature (RT) with 10 mg 
lysozyme, then sonicated (Sonic Dismembrator Model 500, Fisher Scientific) for one 
minute (30% power, 1 second on, 1 second off). The sample was inverted several times 
to ensure mixture of lysate. Sonication was repeated twice more to ensure complete 
lysis. After sonication, the sample was diluted 2.5 fold in Buffer A without Triton-X 100 
(final volume 100 mL, 0.8% Triton-X 100), and spun down at 40,000 g for 45 min 
(Beckman Coulter Optima XL-100K Ultracentrifuge). 
During centrifugation, 12 mL of resuspended cobalt beads (‘Talon metal affinity 
resin’ Clontech) were washed 1x with water, and 2x with Buffer A. Post spin, the 
supernatant was collected and the cobalt beads added for two hours with nutation at 4 
°C. The beads were then collected in an XK16/20 Column (Akta), and eluted using an 
AKTAFPLC chromatography system. It is during this stage that the detergent is 
switched from Triton-X-100 to 1% octyl glucoside (Anatrace). Using a two pump 
protocol, the beads were treated stepwise with varying ratios of two different buffers: 
Buffer B (25 mM HEPES, 100 mM KCl, 1% octyl glucoside, pH 7), and Buffer B-imid, 
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identical to Buffer B but containing 400 mM imidazole. If a construct with a cysteine was 
present, both buffers contained 1 mM neutralized TCEP (Thermo). BME contains a 
thiol, which interferes with the future step of coupling the palmitate. The beads were 
washed with 20 mL buffer B, then 20 mL of 90% Buffer B, 10% Buffer B-imid. Finally, 
the protein was eluted with 20 mL Buffer B-imid, and collected in two mL fractions. After 
the elution, fractions corresponding with the peak of the protein were incubated 
overnight with nutation and ULP1 (1 mM TCEP was added if apoIFITM3 was being 
purified), and analyzed the following day by SDS-PAGE. After cleavage of the SUMO 
domain was confirmed, the appropriate fractions were collected and mixed, and 2 mL 
fractions snap frozen in a dry-ice ethanol bath. Note: Reducing agents such as TCEP or 
DTT are necessary for ULP1 activity. If the sample did not require alkylation with 
maleimide-palmitate (i.e. apoIFITM3), then the SUMO domain was separated from the 
native IFITM3 by size exclusion chromatography (SEC) in Buffer B (10/300 GL, AKTA). 
In our hands, the SUMO domain consistently elutes after the IFITM3, making size 
exclusion a useful method to both remove background proteins as well as the 
enrichment tag. 
Maleimide-Palmitate Synthesis 
Synthesis by Rafal Wiewiora. Protocol from J. Med. Chem., 2009, 52, 7410-7420. 
A round bottom flask was charged with 0.68 g of triphenylphosphine (2.57mmol, 0.9 eq.) 
and 17.5 ml of tetrahydrofuran. The flask was placed under argon and cooled to -78 
°C.1.18 ml of the 40% solution of diethyl azodicarboxylate in toluene (2.57 mmol, 0.9 
eq.) were added over a period of 3 minutes. The resulting mixture was stirred for 5 
minutes, after which a solution of 0.7 g of hexadecan-1-ol (2.87 mmol, 1 eq.) in a 
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minimal amount of THF (prepared in an argon purged vial) was added over a period of 1 
minute. The resulting solution was stirred for 5 minutes. The flask’s septum was then 
removed under the protection of an argon curtain and 0.125 g of neopentyl alcohol (1.43 
mmol, 0.5 eq.) and 0.25 g of maleimide (2.57 mmol, 0.9 eq.) were added as solids. The 
flask was closed again under argon and the reaction mixture was stirred for 5 minutes, 
after which the cooling bath was removed and the reaction stirred at room temperature 
for 16 hours, then at 40 °C for 2 hours. After full conversion was indicated by TLC, the 
solvent was evaporated in vacuo. The resulting solid was purified by silica flash 
chromatography (loading and elution in dichloromethane). N-1-hexadecylmaleimide was 
obtained after high vaccum drying (0.481 g, 52%). 1H NMR (400 MHz, CDCl3) δ ppm 
0.88 (t, J=6.59 Hz, 3 H) 1.25 (br. s., 26 H) 1.53 - 1.60 (m, 2 H) 3.51 (t, J=7.23 Hz, 2 H) 
6.68 (s, 2 H). 13C NMR (100 MHz, CDCl3): δ ppm 14.09, 22.67, 26.73, 28.52, 29.11, 
29.34, 29.46, 29.53, 29.64, 31.90, 37.93, 134.00, 170.87. Reference: J. Med. Chem., 
2009, 52, 7410-7420. 
Maleimide-Palmitate Labeling of IFITM3 
Labeling was completed after cleavage of the His-SUMO-IFITM3 construct with ULP1 
protease. By doing so before the size exclusion, excess mal-palm is removed in 
addition to the SUMO domain and background proteins. Cleaved rIFITM3 is incubated 
with 1 mM TCEP (neutralized) and 0.5 mM Maleimide-Palmitate (stock solution- 10 mM 
in DMSO) for 2 hours at 15 °C with shaking. Temperature control is either by incubation 
in a bacterial incubation shaker while shaking at 100 rpm, or in a cold room on an 
Eppendorf Thermomixer heated to 15 °C. After labeling, the sample is spun down for 10 
min at 20,000 x g and separated by size exclusion chromatography. 
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Confirmation of rIFITM3 maleimide palmitate labeling through MALDI-TOF.  
MALDI –TOF mass spectrometry was of rIFITM3 constructs with generous help of the 
laboratory of Dr. Brian Chait at Rockefeller University. IFITM3 was prepared for MALDI-
TOF analysis using the ultra thin layer method81. Briefly, first a MALDI sample plate was 
prepared with a thin layer of saturated 4-HCCA (Sigma) prior to use (4-HCCA plates will 
last over a year when stored properly). In preparation for sample analysis, (1) 
Eppendorf tubes were washed by vortexing with acetonitrile for several seconds and 
thoroughly dried. (2) A saturated solution of 4-HCCA was prepared by resuspending a 
dried sample of recrystalized 4-HCCA in a solution of formic acid, water, isopropanol 
(FWI) at ratios of 3:1:2 : the dried sample was resuspended in 100 μL isopropanol, and 
rigorously vortexed for 2 minutes. 150 μL formic acid was then added, and the solution 
vortexed rigorously again. Finally, 50 μL water was added, and vortexed a final time. 
The solution was then centrifuged for 6 min at 14,000 rpm, and the soluble fraction 
carefully decanted with a pipette. 
Samples of rIFITM3 were diluted 1/10 in 4-HCCA solution in an acetonitrile 
cleaned tube. The sample was then spotted onto the MALDI sample plate, and 
vacuumed off once a precipitate was seen to form. The spotted sample was then 
washed 2x with chilled 0.1% TFA in water, and loaded within half an hour into the mass 
spectrometer (Spiral TOF JMS-S3000, JEOL). Samples were analyzed at a late pulse 
rate of 500 Hz, at 31-33 % intensity, with a 750 ns lag time between laser pulse and 
sample capture. 
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Chapter 5: Production and anti-viral activity of IFITM3 
proteoliposomes.   
To explore the function of IFITM3 during viral fusion, it is necessary to use an 
appropriate lipid environment. Membrane proteins are purified using a variety of 
amphipathic detergents that enable solubilization by micelles containing hydrophobic 
interiors82. In contrast, viral fusion occurs at phospholipid bilayers, which vary 
considerably from detergents in structure, heterogeneity83, and stabilizing properties84. 
To incorporate rIFITM3 into the phospholipid bilayer, it is necessary to (1) generate the 
lipid bilayer, (2) incorporate the protein, and (3) remove the detergent that could alter 
the membrane properties in future experiments. 
1) Lipid-bilayer formation through liposomes.
A well-established model for investigating membrane proteins in lipid bilayers is 
the liposome. A soluble, single-lamellar spherical bilayer, liposomes can be generated 
from a wide range of lipid compositions and sizes (Table 2). Protein containing 
liposomes (proteoliposomes) have been used extensively to characterize membrane 
proteins85 and protein mediated membrane fusion86, and provide an excellent model for 
viral-fusion inhibition through bulk fusion assays. 
Table 2. Sizes and formation techniques for unilamellar liposomes.  
PC: Phosphatidylcholine. PS: Phosphatidylserine. PE: phosphatidylethanolamine. 






Small Unilamellar Vesicle (SUV) 20 - 100 Sonication  PC/PS/PE87 












For liposome generation in the range of 100 – 1000 nm (large unilamellar vesicle 
- LUV), there are two commonly used techniques – extrusion, and rapid dilution85. For 
extrusion, multi-lamellar liposomes are formed by freeze thawing a detergent free lipid 
solution, and then passed through a filter membrane of defined size until unilamellar 
vesicles are formed. While membranes with pore sizes up to 400 nm diameter can be 
used92, LUV preformation complicates protein incorporation into the lumen. We 
therefore used rapid dilution, which relies on the resuspension of lipids in detergent 
containing buffer (1% w/v octyl glucoside (OG)) then diluting below the critical micelle 
concentration85 (CMC). The CMC is the concentration below which the detergent is no 
longer stable in a micellar structure, leading to its disassembly and inability to solubilize 
hydrophilic domains of lipids or proteins (Fig. 22A). The result of this rapid dilution is the 
spontaneous formation of unilamellar lipid vesicles. 
Proper formation of LUV can be rapidly affirmed through dynamic light scattering 
(DLS), which determines the particle diameter via fluctuations in light scattering and the 
subsequent autocorrelation curve93 (Fig. 22B). Under our formation conditions and lipid 
composition, we consistently observe an average diameter of 80 nm (Fig. 22C). To 
measure the efficiency of liposome formation, a total-phosphate assay94 is used to 
determine phospholipid concentrations after dialysis. We observe similar values for all 
conditions, in the range of 0.5 mM, indicating a lipid retention of ~60% (data not shown). 
2) Incorporation of IFITM3 into the proteoliposomes
In contrast to the extrusion method, a key advantage to liposome formation 
through rapid dilution is the ability to introduce proteins during the formation of the 
liposome itself86. Rapid dilution disrupts the detergent micelle suspension of the both 
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the lipid and recombinant protein, leading liposome formation and protein incorporation 
into the lipid bilayer, with an equal likelihood of incorporation into the lumen of the LUV. 
This is critical for investigating potential IFITM3-virus interactions, the physiological 




Figure 22.  Rapid dilution of detergent solubilized lipid-protein leads to formation 
of unilamellar proteoliposomes. (A) The rapid dilution below the CMC of octyl 
glucoside drives disassembly of the detergent micelle, leading to formation of 
unilamellar LUVs. (B) DLS autocorrelation curves of empty LUVs, proteoliposomes with 
rIFITM3 or VAMP2 show similar trends. (C) Derivatization of LUV diameter from 
autocorrelation curves shows a consistent LUV radius of 40 nm.   
B C
~ 40 nm radius 
A
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3) Dialysis of detergent
With the rapid dilution method, the detergent is diluted to a concentration below 
the CMC (for OG it is approximately 0.6% w/v86) and is no longer in micellar form. While 
the detergent no longer solubilizes rIFITM3 (forcing it into the lipid bilayer), it is possible 
that detergent molecules will intercalate into the membrane, potentially altering the 
biophysical properties of the lipid environment. The final proteoliposomes solution is 
therefore dialyzed overnight in Buffer A without any detergent. After dialysis, the 
liposomes were analyzed for size, and total phospholipid content. 
To confirm the incorporation of the protein into the proteoliposomes, samples 
were centrifuged in a Histodenz density gradient (an alternative to sucrose)95, and 
fractions collected and analyzed by SDS-PAGE. For all protein constructs we observe 
that the majority of the protein distributes to the top fraction of the gradient, reflecting its 
association with the less dense liposome (Fig 23A,B). To enhance detection, the top 
fraction was further concentrated by acetone precipitation. SDS-PAGE shows similar 
signal intensity, further confirming similar levels of incorporation (Fig. 23C).  
As we observed the majority of the rIFITM3 is associated with the 
proteoliposome, we sought to estimate how many proteins are present in each 
membrane leaflet. Values were calculated based off of reported volumes of 
cholesterol96 and PC97, as well as depth of lipid bilayers98. Both starting concentration 
and measured phospholipid concentration (0.5 mM) were determined (calculation in 
methods section). We estimate a final number of 600-1000 IFITM3 molecules per 
liposome (Fig. 24). 
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Figure 23. Protein incorporation into the proteoliposome. (A) Histodenz density 
gradient (0, 30%, 40%, w/v) was spun down at 50,000 rpm with proteoliposome 
containing apoIFITM3 or VAMP2 (protein: lipid 1:1000) and analyzed by SDS PAGE. 
(B) Similar gradient analysis was done on all IFITM3 constructs. (C) Improved signal 
was obtained by acetone precipitation of 250 μL proteoliposomes, and 150 μL first 
fraction of histodenz gradient. Lipid induced mass shift is observed for ML and DL 






Figure 24. Calculation of IFITM3 concentration per LUV and lipid bilayer leaflet. 
(A) Schematic of LUV radius and membrane thickness. Total number of LUV obtained 
by dividing total membrane volume (at 1 mM) by bilayer volume (see methods). (B) 
Histodenz gradients (Fig. 23) suggest the majority of the protein is incorporated into 
LUVs. Dividing the total number of IFITM3 proteins by the number of LUVs yields the 
concentration of IFITM3 / LUV.  
IFITM3 Concentration 
(Protein: lipid ratio) 
IFITM3 Per 
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Bulk Viral Fusion Assay 
The formation of the proteoliposomes is a critical step towards viral fusion 
assays, either in bulk solubilized form, or as an intermediate step towards supported 
lipid bilayers99. To detect the interaction of the virus and the liposome, previous work in 
the literature utilizes self-quenching fluorophores incorporated into the viral 
envelope27,100,101. Catalyzed by the acidification of the buffer solution, hemi-fusion, or 
fusion of the viral envelope with endosome or liposome membrane (reflecting outer-
leaflet mixing, or fusion pore formation, respectively) leads to diffusion of the 
fluorophore, dequenching and increased fluorescent signal (Fig 25). 
Figure 25. DiD labeled IAV enables detection of envelope lipid mixing.  
(A) Structure of DiD, a self quenching fluorophores with high affinity for membranes. 
(B) Schematic for viral fusion assay. Top: Self quenching DiD increases in fluorescent 
intensity upon diffusion into larger membrane area, indicating viral fusion (or hemifusion, 
not shown) has occurred. Bottom: bulk fusion assays provide a first step towards testing 




To support the comparison of our results to previous work in the literature, LUVs 
of similar lipid composition102,103 were used, with molar ratios of 8:2:0.1 
phosphatidylcholine (PC), cholesterol (Chol), hemagglutinin receptor ligand disialo-
ganglioside (GD1a), respectively. As expected, we observed an increase in signal of 
DiD dequenching with GD1a (Fig. 26B). Though previous work has indicated that the 
presence of cholesterol improves viral fusion90, under our conditions similar levels were 
observed when compared with PC and GD1a alone. In contrast, replacing Chol with 
phosphatidylethanolamine (PE), a phospholipid of conical shape104 results in a higher 
DiD signal, confirming that the virus-liposome fusion properties are influenced by our 
choice in lipid composition. 
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Figure 26. Fusion comparison of LUV lipid compositions. Fusion assays were 
conducted at 37 °C, and normalized to the max signal of DiD obtained after the addition 
of 1% Triton X-100. (A) LUVs were prepared from a combination of PC, Chol, PE, and 
GD1a, at identical total concentrations of 1 mM. (B) Same data as A, with PC/PE fusion 




Since the temperature might also affect viral fusion and DiD dequenching, similar 
fusion conditions were compared at 25 °C and 37 °C (Fig. 27). LUV containing VAMP2, 
a SNARE membrane protein105 of similar size to IFITM3 is used as a control for the 
impact of background proteins on viral fusion. While trends between the different 
liposome conditions were conserved, at 37 °C a stronger signal was observed that 
plateaued as early as 15 min into the reaction. In contrast, at 25 °C, DiD dequenching 
was continuous, and did not reach a max value even after 90 min. As 37 °C not only 
results in faster results that go to completion, but also reflects the physiologically 
relevant temperature, all further experiments were conducted under similar conditions. 
To show that DiD dequenching was not an artifact of the model, we tested the 
functional conditions of the DiD labeled IAV (Fig. 28). IAV fuses with the lipid bilayer of 
the late endosome at a pH below 5.5 106 , leading to fusion pore formation and content 
release. Fusion should therefore only occur in the presence of an intact viral particle, 
LUV, and acidic buffer conditions (pH 5). When comparing IAV alone at pH 5, or IAV 
with LUV at pH 7, neither show a significant increase in signal in comparison to IAV with 
LUV, at pH 5. This indicates that minimal DiD dequenching occurs due to acidification of 
the buffer or spontaneous transfer of DiD from the viral membrane to the LUV. Previous 
work by Carr et al.107 showed that IAV fusion can be disrupted by premature unfolding 
of the hemagglutinin (HA), caused by either heating at 62 °C for 30 min or premature 
acidification at pH 5. Indeed, both conditions disrupted viral fusion in our assay, 
supporting our model that DiD dequenching is mediated by HA catalyzed lipid mixing 
(fusion/hemifusion). 
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Figure 27. Temperature of IAV fusion affects rate, and signal saturation. LUV and 
VAMP2 proteoliposomes were incubated with DiD labeled virus at pH 5, at 25 °C (A) 




Figure 28. Viral fusion with LUV is pH, HA dependent. . Minimal signal was observed 
under similar conditions at pH 7, or in the absence of LUV. To confirm that HA integrity 
was required for fusion, IAV was incubated either at 62 °C for 30 min (HK), or incubated 
at pH 5 at 37 °C (preprimed). Both conditions compromise fusion, and DiD 
dequenching.  
Having characterized the LUV and viral parameters of our model, we proceeded 
to fusion assays with LUVs containing rIFITM3. Starting with protein concentrations 
similar to other LUV fusion models we titrated the amount of VAMP2 (Fig. 29A) and 
apoIFITM3 (Fig. 29B) to determine the dynamic range and saturating concentrations. 
Both exhibited a decreasing DiD fluorescence signal at lower protein concentrations, 
indicating non-saturating conditions in the protein:lipid range of 1:1000-1:4,000. 
We first compared viral fusion with proteoliposomes of VAMP2 and apoIFITM3 at 
protein:lipid ratios of 1:1000 to facilitate detection and maximize signal (Fig. 30). Though 
our data indicates apoIFITM3 is a non-physiologically occurring phenotype (Fig. 17C) it 
provides a first step towards understanding whether S-fatty acylation is critical for 
IFITM3 function (in contrast to trafficking or turnover). It also provides a critical control 
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for modified lipidated constructs. Viral fusion with LUV containing VAMP2 exhibited DiD 
dequenching equivalent to roughly 80% of the empty LUV.  Due to high concentrations 
of LUV and virus, we hypothesize this is due to background lipid mixing mitigated by 
VAMP2 steric hindrance. ApoIFITM3 showed a greater inhibition of DiD dequenching 
with max levels reaching approximately 65%, providing first evidence of a direct 
interference with viral fusion. Though promising, a helpful control is the loss of function 
through the mutation of additional sites. Earlier work by John et al.10 demonstrated 
several point mutations that disrupt the anti-viral activity of IFITM3. Two of these (R85A, 
T99A) do not disrupt the addition of PTMs, but rather interfere with the native amino-
acid backbone. We therefore generated apoIFITM3-R85A as a control mutant. 
Unexpectedly we found it showed similar levels of inhibition to that of the apo-WT. As 
this mutation might be non-disruptive under the conditions of the fusion model, we are 
continuing our efforts towards functional mutants, with additional point mutants as well 
as larger, more disruptive modifications. 
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Figure 29. Titration of VAMP2 and apoIFITM3 confirms dynamic range of 
proteoliposome fusion assay. Both VAMP2 (A) and apoIFITM3 (B) were titrated intro 
proteoliposomes at the reported ratios, and the DiD signal normalized to the max DiD 




Figure 30. ApoIFITM3 inhibits viral lipid mixing to a greater degree than VAMP2. 
Proteoliposomes at a protein:lipid ratio of 1:1000 were incubated with DiD labeled virus 
at pH 5, and normalized to the max DiD value of empty LUVs. ApoIFITM3 (yellow) and 
R85A (red) show similar levels of activity. Representative of duplicate experiments.  
Error bar represents SD. 
Having observed a decrease in DiD dequenching with apoIFITM3 
proteoliposomes, we proceeded to compare IAV fusion with proteoliposomes containing 
the various lipidated constructs described in chapter 4 (Fig. 20). To test whether the 
constructs showed similar activity levels, we titrated the mono-lipidated constructs over 
a protein:lipid range of 1:1000–1:20,000 (Fig. 31). All constructs showed a 
concentration dependent increase in inhibition of DiD dequenching, while C105A 
appeared to inhibit DiD more effectively than apoIFITM3 (Fig. 31A). To facilitate 
experimental design, and inclusion of the double-labeled C72,105 construct (protein 
instability resulted in very low protein purification), a protein:lipid ratios of 1:5000 was 
chosen for subsequent experiments. 
*
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Figure 31.  All constructs of rIFITM3 inhibit viral lipid mixing. (A) Decreasing ratios 
of protein:lipid (higher protein concentration) increase efficacy of inhibition of mono-
lipidated constructs (ML Cys 72, ML Cys 105). Representative of duplicate experiments. 
Error bars represent SD. (B) % DiD inhibition (1-max fusion value) at protein:lipid ratio 
of 1:5000.  
Biological replicates indicate that the apoIFITM3 proteoliposome inhibits DiD 
dequenching in comparison to VAMP2 or empty LUVs (Fig. 32). ML-C72 does not alter 
IFITM3 inhibition activity, while ML-C105 shows a significant increase of 50% (+/- 29% 
SD). Surprisingly the double lipidated construct shows a smaller improvement, inhibiting 
DiD dequenching by 30% (+/- 22%- SD). This data indicates that rIFITM3 independently 
alters some aspect of the fusion environment that interferes with hemifusion/fusion and 
DiD dequenching. Furthermore, lipidated isoforms have Cys-specific affects on rIFITM3 
mediated inhibition, with ML-C105 increasing rIFITM3 activity the most. One 
interpretation is that the S-fatty acylation of C72, previously shown to be critical for 
A B 
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IFITM3 anti-viral activity (Fig. 17) plays a role in IFITM3 trafficking and regulation, while 
S-fatty acylated C105 augments IFITM3 function. While this model holds promise, more 
work is required to correlate the data with in vitro work, such as introduction of rIFITM3 
isoforms to tissue culture, or better mimics of the late endosome membrane. 
Figure 32. Cys specific lipidation of rIFITM3 alters inhibition of DiD dequenching. 
Pooled data of four separate fusion assays comparing apoIFITM3 with mono and dual-
lipidated rIFITM3 constructs. Protein:lipid ratio for all experiments 1:5000. Error 
represents SD. P<0.05 for unpaired, two-tailed t-test.  
To test that the difference in inhibition between apoIFITM3 and ML-105 
proteoliposomes is not due to residual mal-palm from the labeling and purification 
process, apoIFITM3 was purified a similar manner to ML-105. Comparison of 
apoIFITM3 with and without mal-Palm showed identical levels of inhibition of viral fusion 
(Fig. 33A). A drawback of the reconstituted bulk fusion assay is the stochastic 
incorporation of rIFITM3 into both sides of the liposome membrane. While this insures 
*
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the incorporation of rIFITM3 into the LUV lumen, it also results in virus-facing rIFITM3, 
which does not occur under physiological conditions (Fig. 4). To remove outer-leaflet 
rIFITM3, we incubated the proteoliposomes for 1 hour with chymotrypsin(Fig. 33B). 
While we observed proteolysis of all constructs (Fig. 33C), we did not observe a 
change between the extent of inhibition between cleaved and non-cleaved samples. 
There are several possible interpretations: (1) the outer leaflet rIFITM3 does not play a 
role in viral fusion, with all anti-viral activity exerted by the luminal facing fraction. (2) 
The transmembrane domain of the outer-leaflet rIFITM3 contributes to anti-viral activity, 
and is retained after chymotrypsin treatment. (3) The cleaved rIFITM3 still adheres to 
the LUV membrane and exerts some activity during viral fusion. While this problem can 
be better addressed by generating a single-orientation topology, we are unaware of any 
techniques that can encapsulate a protein in a liposome, or supported bilayer, without 
relying on further proteolysis. Future options for fusion models are discussed in Chapter 
6.
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Figure 33. Residual mal-palm, chymotrypsin treatment does not alter proteo-
liposome fusion properties. (A) Purification of apoIFITM3 under similar mal-palm 
labeling conditions as ML-C72/105 does not alter the % inhibition of DiD dequenching in 
viral-proteoliposome fusion assays. Protein:lipid 1:5000, (B) Proteoliposomes with or 
without chymotrypsin were incubated for 1 hr at 37 °C. After viral fusion assays, the max 
DiD value for each condition was normalized to the max value of LUV alone. (C) SDS-
PAGE of proteoliposomes treated with chymotrypsin. Lower molecular weight bands are 




Methods for Chapter 5: 
Generation of proteoliposome through the rapid dilution method: 
Modified from Weber et al. 86. All chloroform solutions were stored in appropriate 
borosilicate glass with PTFE lined caps (VWR). Phosphatidylcholine and 
phosphatidylethanolamine, suspended in chloroform were purchased from Avanti lipids. 
10 mg cholesterol (Sigma) was resuspended in 1 mL HPLC grade chloroform (Sigma), 
for a final concentration of 25.88 mM.  GD1a (Sigma) was resuspended in a 1:2 
methanol:chloroform solution, for a final concentration of 0.544 mM (mw 1882).  
For a final total concentration of 1 mM lipid (cholesterol included), appropriate 
volumes of each lipid were added to a 13 x 100 mM glass vial, and dried under a gentle 
argon stream (a clear reside is observable from at the bottom of the vial). The sample 
was then placed under vacuum for at least 2 hours. The dried lipid was resuspended in 
1/4 the final total volume by adding Buffer A containing 1% OG, followed by horizontal 
shaking (gentle agitation can also be used). Higher resuspension concentrations will 
result in an opaque solution. The resuspended lipid was then aliquoted to other glass 
vials according to the number of conditions planned. After the addition of protein (the 
volume of protein + lipid cannot exceed 1/3 final volume), the lipid-protein solutions 
were left at RT for several minutes, then rapidly diluted: on a table top vortex machine 
turned to a high setting, the glass vial was pressed down with one hand, while the other 
hand added 2-3x the volume of the solution, of buffer A without detergent (depending on 
starting volume). This dilutes the OG below the CMC of 0.5% (final 0.25 – 0.3 %), 
driving the formation of liposomes. 
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To dialyze out the remainder detergent, the entire liposome solution was added 
to pre-primed Slide-A-Lyzer MINI Dialysis wells (Thermo, 10k MWCO). Different sized 
wells were used depending on the volume of the solution (0.5 mL wells for 4-500 μL 
volumes, 3 mL wells for 1-2 mL volumes). The wells were then shaken horizontally at 
RT for 1 hr, followed by a buffer exchange and dialysis with horizontal shaking for 6 hr 
at 4 °C. Finally, an additional buffer exchange was done, and incubated overnight at 4 
°C with horizontal shaking. The next day, the samples were transferred to Eppendorf 
tubes with a pipette, and used for the described assays. Samples were kept for a 
maximum 1 week at 4 °C. 
DiD labeling of IAV 
For DiD labeling of IAV, the protocol reported by Desai et al.27 was used with 
minor modifications: 200 mg virus (Charles River, catalogue# 10100374, 2 mg/mL, 
thawed once and snap frozen in 50 μL aliquots, in liquid nitrogen) was diluted in 300 μL 
50 mM sodium bicarbonate buffer (pH 9.0), and incubated with 13.2 μL DiD (Thermo) 
for 90 min shaking at RT. During this period, a disposable sephadex column (PD 
MiniTrap G-25, GE) was washed 3x with buffer A. To remove excess DiD, the sample 
was then added to the column, followed by 100 μL buffer A. The column was then 
transferred to a new 15 mL Falcon tub, and eluted with 1 mL of buffer A. The eluted 
virus was kept away from light and on ice until use. 
For a higher concentration of viral particles, it is possible to pass them through 
the G-25 column while centrifuging at 300 x g (see product manual). Though this 
removes excess DiD, it does not switch to a more neutral buffer. Care should be given 
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to adjusting acidification volumes during fusion experiments. DiD labeled IAV was 
usually prepared fresh the day of a fusion experiment, and surplus kept at most 48 hrs 
for additional use.  
Dynamic Light Scattering (DLS) for measuring proteoliposome diameter. 
Proteoliposome size was confirmed using a Wyatt DynaPro DLS Detector II. DLS 
is particularly sensitive to background contaminants, so extra care should be given 
during sample preparation, such as using Eppendorf tubes with minimal air exposure. 
Buffer A prepared with LCMS water (Spectrum Chemical) was filtered with a 0.02 μm 
filter (Whatman). Online protocols recommend 0.1 – 0.2 μm filters, though background 
signal was observed with our reagents. In 1.5 mL Eppendorf tubes, 200 μL of filtered 
buffer A was aliquoted. 2 μL of the sample (1/100) was added to the tube, and inverted 
several times to mix. All samples were then centrifuged for 5 min at 20,000 x g at RT, 
and three, 60 μL aliquots made in a 384 flat well plate (Greiner). Each sample was 
measured 10 times, 10 seconds per measurement. 
Phospholipid Quantification. 
To determine the total lipid concentration, a total phosphate assay was 
generously provided by the Menon Lab at Weill Cornell94. In 13 x 100 mm glass tubes, a 
standard was prepared from a 40 mM Na2HPO4  stock solution, of 0, 2, 5, 10, 20, 50, 80 
nmol phosphate (Pi), with a final volume of 50 μL. 10 μL of each lipid samples were 
then added to additional tubes with 40 μL H2O. 300 μL perchloric acid (HClO4, Sigma) 
was added to all conditions, and heated for 1 h at 145 °C. (marbles on the tubes prevent 
evaporation). The tubes were then removed from the heating block, 1 mL H2O was 
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added, and the solution vortexed briefly to mix. Samples were then left to cool while 
preparing 12mg/mL molybdate tetrahydrate (6 mL Sigma) and 50 mg /mL ascorbic acid 
(6 mL, MP Biomedicals ). 400 μL of each was then added to each tube, and vortexed to 
mix. The tubes were then heated at 100 °C for 10 minutes (make sure the tubes are on 
the same heating block, as heating variation will skew results), and cooled again to RT. 
200 μL of the standards and samples were then aliquoted in duplicate to a 96 well plate, 
and their absorbance measured at 797 nm (minimal color variation will appear in the 
lower Pi concentrations and sample). 
Theoretical Calculation of rIFITM3 particles / liposome. 
For calculating the theoretical number of IFITM3 proteins per LUV, the 
membrane thickness was assumed to be 3.7 nm98., and the volumes of cholesterol96, 
and PC97 to be 0.622 nm3 and 1.256 nm3 respectively. Assuming an equal lipid 
concentration on each leaflet of the bilayer: 




       3 - 𝑅𝐿𝑢𝑚𝑒𝑛 
             3)=  
4
3
 𝜋 (40nm3 – 
(40 (47)nm3)  =  67,723 nm3
2) Total number of LUV = Total volume of lipids / volume of lipid bilayer
Total volume of 1 mmole lipids = 10−3 ∗ 6.022 ∗ 1023(0.8 ∗ 1.256 nm3 +  0.2 ∗
0.622 nm3 =  6.8 ∗ 1020nm3 
Total number of LUVs = 6.8 ∗ 1020nm3  / 67,723 nm3= 1.005∗ 1016 = 1.667 nmole  
1.667 nM for 1 mM solution of lipids.  
3) Number of IFITM3 proteins / LUV = [IFITM3]/ [Concentration LUV]
e.g.  0.2 μM IFITM3 / 1.667 nM LUV = 120 IFITM3 proteins / LUV 
73 
Fusion assay to measure DiD dequenching 
For all fusion assays, a digital multi-pipettor was used to enable simultaneous 
acidification of multiple conditions.  40 μL of LUV were added in triplicate to a 384 flat 
well plate (Greiner) with 20 μL virus. After 5 minute incubation, the solution was acidified 
with 4 μL of 50 mM, pH 4 sodium acetate (1/15 of starting volume, final pH 5.0). 
Conditions kept at pH 7 were adjusted with 4 μL buffer A. Immediately after acidification, 
the plate was measured on a pre-heated BioTek Synergy Neo at 37 °C. Measurements 
were taken every 2:30 min, over a period of 40 min, at excitation/emission of 640/670. 
After each run, 2 μL of 20% Triton-X 100 was added to all wells to completely solubilize 
the DiD and obtain a max signal for reference and normalization. 
Data analysis of fusion data. 
For data analysis, each time point was normalized to the max DiD signal in the well 
obtained after addition of Triton-X-100.  Technical replicates were then averaged, and 
divided by the max value obtained for LUV alone. This results in a normalized DiD 
dequenching curve in reference to LUV max fusion. 
Chymotrypsin proteolysis of outer leaflet rIFITM3 
Buffer A (negative control) or chymotrypsin (Promega, 25 μg resuspended in 50 μL 50 
mM NH4CO3 pH 8) was added to LUV samples at a IFITM3:chymotrypsin ratio of 10:1, 
for 1hr at 37 °C. 20 μL was then aliquoted for analysis by SDS-PAGE, and 80 μL used 
for the fusion assay. 
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Chapter 6: Future directions for rIFITM3 assays 
Our proteoliposome-viral fusion assay with rIFITM3 presents the first evidence 
that a potential mechanism of IFITM3 viral inhibition is by independently altering the 
fusion environment. To investigate the viral fusion mechanism further the current model 
needs to be improved, having been originally built off a variety of assays previously 
used in the literature (proteoliposome formation86, lipid composition103, viral labeling27). 
This setup was initially to our advantage as it allowed us to compare our results to 
previous work, and provided a framework to build upon. To determine how IFITM3 
might be altering the membrane environment though, we require new assays to detect 
content mixing and fusion pore formation, and a better mimic of the late endosome 
environment. 
Content Mixing Assays: 
A facile modification of viral envelopes, the self-quenching properties of DiD 
labeling provides a valuable tool for measuring viral fusion. But while DiD can indicate 
the initiation point of lipid mixing, it cannot be used to distinguish between hemi-fusion 
(the mixing between the outer leaflets of the opposing membranes) and formation of the 
complete fusion pore. This is critical in understanding the mechanism of IFITM3, which 
has been suggested to interfere with viral fusion and content delivery at the stage of 
hemi-fusion27. To be able to distinguish between the two possible stages, future work 
will focus on improving our model to detect full fusion pore formation, and pursuant viral 
content delivery. 
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Measuring content delivery between two populations of liposomes has been 
previously reported, using fluorescent dequenching108, or FRET109,110. These assays are 
based on encapsulation of two reacting moieties, which is incompatible with our viral-
LUV model. However, they provide an experimental framework and possible tools for 
future use. For viral content labeling, one reported method relies on passive diffusion 
across the viral membrane with self-quenching Sulforhodamine B103. While the method 
has been used in singe particle measurements, we have not been able to replicate 
these results in our bulk fusion assay due to background signal. An additional assay is 
the incorporation of fluorescent proteins and probes into the viral nucleocapsid27,111. 
Though useful for microscopy-based tracking of content delivery, this approach is 
hindered by lacking a gain, or loss of signal. 
To address these technical limitations, our future work will focus on exploring two 
possible mechanisms for content labeling of viral particles. Both rely on a change in 
fluorescent activity (loss or gain), but vary in our incorporation methodology. 
1) Incorporation of unnatural amino acid through amber suppression technology.
Amber-codon suppression has proven an invaluable tool for incorporating unnaturally 
occurring (synthetic) amino acids (UAA) with functionalized moieties112. This technique 
has been used extensively to introduce novel functionalities into proteins, including 
photo-activated capture based screens113,114, and post-translational labeling of 
IFITM3115. Previous work by other labs has successfully incorporated synthetic amino 
acids into viral capsid116,117 and envelope118 proteins, suggesting UAA incorporation 
provides a powerful tool for the modification of the influenza nucleocapsid. 
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Our first step would be to optimize the incorporation of an unnatural UAA into the 
most abundant nucleocapsid protein M1 (which not exposed to the buffer solution). This 
UAA could contain either a trans-cyclooctene (TCO) that reacts with several tetrazine 
containing fluorophores115, a fluorescent molecule incorporated during viral particle 
assembly to be further quenched during exposure to the LUV lumen, or a nucleotide 
sequence disrupting FRET based signal as previously reported in the literature110. 
2) Labeling of viral lumen through membrane permeable probes.
An appealing alternative to incorporating the chemical probe during particle assembly 
(requiring purification) is the labeling of intact viral particles. This is both more time 
effective, and simultaneously applicable to multiple viral samples, enabling strain, 
species, and clinical sample comparisons. 
A technical difficulty of this model is the necessity of choosing a chemical probe 
that can (1) selectively permeate across the viral envelope, and (2) be retained within 
the interior. To address this we can utilize a membrane permeable transcycloctene 
(TCO) or cyclooctyne derivative (BCN)119, coupled to an amine reactive NHS–Ester120 
or photo-coupled diazirine114 for retention within the viral capsid (Fig. 34A). Preliminary 
data indicates that a BCN-NHS-Ester can successfully label both envelope proteins as 
well as M1 (Fig. 34D). This provides first evidence that the TCO moiety can successfully 
transverse the viral membrane, and label capsid proteins. 
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Figure 34.  Labeling of IAV with BCN-NHS-Ester enables fluorescent detection of 
IAV capsid proteins by SDS-PAGE. (A) Membrane permeable BCN-NHS probes can 
label M1 protein in intact viral particles, and is later labeled with TCO-tagged 
fluorophores. (B) List of IAV proteins and their corresponding molecular weight. NS1 is 
not present in the viral capsid. (C) Identification of IAV proteins separated by SDS-
PAGE and stained with coomassie blue (D) Labeling of IAV with BCN-NHS-Ester. Virus 
was diluted 1/4 in pH 9 buffer and labeled for 1 hr at RT before excess BCN was 
removed by a desalting column, and incubated with 1 mM tetrazine-BODIPY for 15 min. 





Mimicking Late Endosome Lipid Composition. 
Due to the relatively small size of IFITM3, its unknown mechanism, and broad–
spectrum anti-viral activity (Table 1), it is believed IFITM3 inhibits viral fusion by the 
alteration of the fusion environment, in particular the biophysical/mechanical properties 
of the endosomal membrane. Therefore, the impact of lipid composition choices in our 
fusion model must be considered, regardless if done via bulk fusion or supported lipid 
bilayer. While nearly all membranes are comprised of approximately 70% 
phosphatidylcholine, the remaining lipid composition of lipid species and cholesterol 
varies significantly by organelle104. In the literature of bulk liposome fusion assays, a 
large fraction of the work is focused on protein-catalyzed membrane fusion with LUVs 
mimicking the plasma membrane121 and synaptic vesicles122. For late endosome lipid 
composition, there is a paucity of information, the most detailed analysis currently 
available having been determined with hamster kidney cells123 (Fig. 35). And while our 
understanding of cholesterol trafficking is making strides the field has only a qualitative 
understanding that little cholesterol is retained within the limiting membrane during 
endosome maturation40,124. Nonetheless, to better emulate late endosome lipid 
composition. Our future work will transition away from the literature used ratios of 80% 
PC, 20% Chol103. To simplify the complexity of the late endosome, a 3 component 
membrane will be used that accounts for main sources of charged lipids, and steric 





















Figure 35.  Lipid composition of the late endosome, and proposed mimic.   
(A) Kobayashi et al.123, isolated late endosomes from baby hamster kidney (BHK) cells 
and determined their composition by TLC and autoradiography. (B) To emulate the late 
endosome environment, and reduce the complexity from 7 to 3 different lipids, we 
propose using PC, PE, and PS to mimic contributing factors of shape and charge.  
Single particle and supported bilayer: 
The analysis of viral fusion through bulk assays provides a straightforward 
approach to understanding the change in the average total fluorescent signal. But even 
should we be able to successfully detect the occurrence of content mixing as described 
earlier in the chapter, limitations to the model obscure critical information, such as what 
fraction undergoes hemifusion and what fraction complete fusion? Are there changes in 
the fusion rates? In the fusion pore size? Furthermore, the smaller size of LUV (80 nm 
diameter) results in a surface area of significantly higher membrane curvature in 




To better characterize the fusion event, we intend to conduct single particle 
measurements on a supported lipid bilayer, using total internal reflection fluorescence 
(TIRF) microscopy126. This model utilizes a single, planer lipid-bilayer assembled from 
preformed liposomes, and can be supported by a PEG127,128 or dextran129 cushion, 
enabling lipid mobility and space for protein activity. The use of TIRF, with a depth of 
field of 60-200 nm126 excludes background signal of viral particles not present at the 
lipid membrane, enabling single particle resolution. This technique has been used 
extensively to investigate vesicle130, and viral fusion131, and has can resolve the spatial 
and temporal progression of single fusion events132,133, providing crucial information as 
to the dynamics of lipid mixing, and fusion pore formation (Fig 36).  
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Figure 36. Single particle measurements for improved characterization of viral 
fusion. Supported lipid bilayers can provide a useful tool for investigating IFITM3 
restriction of viral fusion, distinguishing between hemifusion and fusion, as well as 
measuring other parameters such as fusion kinetics, IFITM3 colocalization (with proper 
labeling), and membrane fluidity.   
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Discussion: 
Extensive research conducted over the past nine years provides considerable 
support to the idea that IFITM3, as well as other members of the IFITM family, plays a 
significant role in the first line of defense against most clinically relevant viral pathogens 
encountered in the past century. Despite several reports of inflammatory regulation20,42, 
the literature indicates that the point of interference occurs prior to viral fusion and 
content delivery 27,38,134,135. 
As such IFITM3 receives a unique classification: it is part of a group of innate 
immunity mechanisms that occurs prior to a viruses’ ability to introduce their varied 
methods of virulence or immune evasion136. This distinction increases the importance of 
elucidating its mechanism, in particular due to emerging evidence for mutations in 
human and avian IAV that can bypass IFITM3 inhibition18,137, as well as recent reports 
that both IFITM2 and IFITM3 play an role in inhibiting HIV infection30,31 (Fig. 37). 
Figure 37. IFITMs’ interference with viral fusion and entry is a unique antiviral 
mechanism. IFITMs belong to a small group of innate immunity proteins that disrupt 
infection prior to entry and the release of viral evasion mechanisms, such as 
antibodies138, complement system proteins139, and defensins140. Even more uncommon 
is its inhibition at the point of fusion, which we understand to be the only known protein 
to directly do so. Viral entry is also inhibited by the upregulation of 25-
hydroxycholesterol141.   
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Earlier work has provided first indicators of possible antiviral mechanisms, with 
no definitive results27,34,39. The complexity of the cellular environment prompted us to 
approach the question through the use of a recombinant fusion model. We asked 
whether we could recapitulate the inhibition of viral fusion in a model system containing 
a lipid bilayer with IFITM3. This model system would provide first evidence that perhaps 
one of the mechanisms of IFITM3 is by a direct interaction with the fusion environment. 
These efforts were enhanced by our development of the mass-shift based Acyl 
Peg Exchange (APE) assay, that enables the simultaneous detection of multiple S-fatty 
acylation levels of endogenous proteins71. This method addresses a significant limitation 
to the field of S-fatty acylation, which until now could only assess total changes in 
protein S-fatty acylation, and could not validate the existence the simultaneous S-fatty 
acylation events. APE makes it possible to detect physiological S-fatty acylation levels, 
as well as compare different tissues, time points, inflammatory conditions etc. The 
analysis of endogenous IFITM3 by APE provided several key findings critical to our 
future work with recombinant IFITM3; both mouse and human endogenous IFITM3 
showed no detectable levels of non-modified (apo) protein (Fig. 16,17), indicating that 
all IFITM3 is S-acylated at least once. Furthermore, mouse and human cell lines 
showed differing S-fatty acylation levels. While mIFITM3 appeared to have equal levels 
of all three S-acylation states, hIFITM3 exhibited only two, with the majority of the 
protein being dually-S-acylated (Fig. 17). 
Our improved understanding of IFITM3 S-acylation proved critical in generating 
recombinant protein, and emulating specific S-acylation states by mal-palm labeling 
(Fig. 20). Our purification protocol enables the generation of several mg of protein, does 
84 
not introduce denaturing conditions during enrichment17,142, is purified from widely 
accessible bacterial culture, and contains confirmed, non-reversible covalent 
modifications mimicking S-fatty acylation. 
Finally, the successful preparation and characterization of IFITM3 
proteoliposomes paved the way for our first steps towards measuring IFITM3 impact on 
the viral fusion. Our observation that in the presence of IFITM3, DiD dequenching is 
impaired suggests an IFITM3 mediated decrease in efficiency of viral hemifusion/fusion. 
This provides first, preliminary evidence is that IFITM3 can independently exert its anti-
viral activity, and that the mechanism is either by interacting with the virus directly or 
through altering the membrane environment. Broad antiviral activity, and reports in the 
literature that hemagglutinin mediated cell-cell fusion can be inhibited by IFITM326,34 
provides further support in favor of an alteration to the membrane environs. 
With respect to the specific effect IFITM3 is exerting on the membrane environs, 
we have yet to apply the necessary assays capable of testing current hypotheses. It is 
possible IFITM3 alters the physical properties of the membrane, such as membrane 
fluidity, rigidity, or lipid spatial distribution. Alternatively, IFITM3 might directly exert a 
steric/entropic inhibition at the site of fusion itself, either in the form of the hemifused 
stalk, diaphragm143. 
We believe our results justify further work, though the bulk fusion model has 
several limitations that would be overcome by an improved experimental setup. Future 
experiments will explore single particle tracking - a model that can better mimic the lipid 
curvature and composition of the physiological viral-fusion environment, as well as work 
to detect content mixing and IFITM3 organization around the fusion locus. 
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We believe this data is a promising first step towards understanding the 
mechanism of IFITM3. The use of a recombinant system holds promise as a tool that 
can rigorously control and monitor the various parameters that will enable us to 
elucidate the molecular basis of IFITM3 inhibition in the membrane environment. 
Combining this with future structural and in vitro assays, we look forward to expanding 
our knowledge if this critical protein. 
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